Fox Corp. has agreed to acquire streaming platform Roku in a cash-and-stock deal valued at about $22 billion, including debt, in a move that would significantly expand the media company's digital reach and reshape the US television landscape.
The deal combines Fox's portfolio of live sports, news and entertainment content with Roku's connected-TV operating system and advertising platform, creating what the companies described as a scaled, next-generation media and technology company.
Fox said the combined company would become the third-largest player in the US television market by share of viewers, underscoring the growing importance of streaming distribution in the media industry.
"This is a defining moment for Fox," Chief Executive Lachlan Murdoch said in a statement announcing the agreement.
Roku Chief Executive Anthony Wood said the platform currently reaches more than 100 million households globally and framed the deal as a chance to accelerate growth.
"The combination with Fox is an extraordinary opportunity to accelerate our vision, scale faster and innovate more aggressively for viewers, partners and advertisers," Wood said.
Under the terms of the transaction, Fox will acquire Roku for $160 per share through a combination of cash and Fox Class A common stock.
Fox shareholders are expected to own about 73% of the combined company, while Roku shareholders will hold the remaining stake.
The boards of both companies have approved the transaction. Wood will remain involved with the combined company and join Fox's board after the deal closes.
Wall Street's initial response was mixed.
FOX shares fell about 13% in premarket trading, reflecting investor concerns about dilution and the risks that often accompany large acquisitions financed partly with stock.
Roku shares rose 1.7% to $146.11 in premarket trading, extending gains from Friday when the stock jumped more than 20% following reports that the company had been exploring a sale and holding talks with at least one major media company.
Fox said it will fund the cash portion of the deal using cash on hand and new debt financing, including a $12 billion bridge facility.
The company is targeting approximately $400 million in annual cost synergies and expects the transaction to become accretive to free cash flow per share by the second full year after closing.
Brokerages broadly viewed the deal as strategically significant for both companies.
Needham raised its price target on Roku to $170 from $140 while maintaining a Buy rating, citing the strategic value of Roku's position in the streaming ecosystem.
Citizens also lifted its target to $175 from $170 and reiterated a Market Outperform rating.
Analyst Matthew Condon said Roku's dominance in connected television made it an attractive acquisition target.
Roku accounts for 44% of streaming time in the United States, according to Comscore, and, as the leading television operating system, reaches more than half of US broadband TV households, Citizens noted.
JPMorgan analysts argued that the acquisition could fundamentally reposition Fox toward digital streaming and help address long-standing investor concerns about the company's dependence on traditional pay-TV.
"A Roku deal would fundamentally pivot the business toward digital and answer long-term concerns about a legacy in PayTV," the analysts wrote.
They added that Fox would gain direct digital distribution into more than 100 million households for its sports, news, and entertainment programming, while also strengthening its position in the fast-growing free ad-supported streaming market through a combination of Roku's platform and Fox-owned Tubi.
Integration risks remain a key concernDespite the strategic rationale, analysts also warned that integrating a major technology platform into a traditional media company could prove challenging.
JPMorgan cautioned that Roku ownership could introduce execution risk and operational complexity into what has otherwise been a relatively straightforward investment story for Fox.
The deal also comes at a time when media companies are under pressure to build profitable streaming businesses while managing the decline of traditional cable television.
For Fox, which has long relied on live sports and news to maintain relevance in the cable era, the acquisition represents its boldest attempt yet to secure a stronger position in the streaming economy.
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.
The Zacks Premium service, which provides daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter, makes these more manageable goals. All of the features can help you identify what stocks to buy, what to sell, and what are today's hottest industries.
Also included in Zacks Premium is the Focus List. This is a long-term portfolio of top stocks that have all the traits to beat the market.
Breaking Down the Zacks Focus ListIf you could, wouldn't you jump at the chance for access to a curated list of stocks to kickstart your investing journey?
That's what the Zacks Focus List, a portfolio of 50 stocks, offers investors. Not only does it serve as a starting point for long-term investors, but all stocks included in the list are poised to outperform the market over the next 12 months.
What makes the Focus List even more helpful is that each selection is accompanied by a full Zacks Analyst Report, which explains the reasoning behind every stock's selection and why we believe it's a good pick for the long-term.
The portfolio's past performance only solidifies why investors should consider it as a starting point. For 2020, the Focus List gained 13.85% on an annualized basis compared to the S&P 500's return of 9.38%. Cumulatively, the portfolio has returned 2,519.23% while the S&P returned 854.95%. Returns are for the period of February 1, 1996 to March 31, 2021.
Focus List MethodologyWhen stocks are picked for the Focus List, it reflects our enduring reliance on the power of earnings estimate revisions.
Earnings estimates are expectations of growth and profitability, and are determined by brokerage analysts. Together with company management, these analysts examine every aspect that may affect future earnings, like interest rates, the economy, and sector and industry optimism.
What a company will earn down the road also needs to be taken into consideration, and this is why earnings estimate revisions are so important.
When a stock receives upward earnings estimate revisions, it will likely get even more positive changes in the future. For instance, if an analyst raised their earnings outlook last month, they'll probably do so again this month, and other analysts will follow.
Harnessing the power of earnings estimate revisions is where the Zacks Rank comes in. The Zacks Rank is a unique, proprietary stock-rating model that utilizes changes to a company's quarterly earnings expectations to help investors build a winning portfolio.
The Zacks Rank consists of four main pillars: Agreement, Magnitude, Upside, and Surprise. Each one is given a raw score, which is recalculated every night and compiled into the Rank. Then, stocks are classified into five groups, ranging from "Strong Buy" to "Strong Sell," using this data.
The Focus List is comprised of stocks hand-picked from a long list of #1 (Strong Buy) or #2 (Buy) ranked companies, meaning that each new addition boasts a bullish earnings consensus among analysts.
It can be very profitable to buy stocks with rising earnings estimates, as stock prices respond to revisions. By adding Focus List stocks, there's a great chance you'll be getting into companies whose future earnings estimates will be raised, which can lead to price momentum.
Focus List Spotlight: CBRE Group (CBRE - Free Report) CBRE Group, Inc. is a commercial real estate services and investment firm headquartered in Dallas, TX. It provides leasing, property sales, commercial mortgage origination, loan servicing, valuations and other advisory services to tenants, owners, lenders and investors across major global markets. The company also provides facilities management, property management and workplace experience services through its Building Operations platform and delivers program management, project management and cost consultancy through Turner & Townsend. CBRE also operates an investment management business and a real estate development business under its Real Estate Investments segment.
On March 13, 2017, CBRE was added to the Focus List at $36.4 per share. Shares have increased 266.51% to $133.41 since then, and the company is a #2 (Buy) on the Zacks Rank.
For fiscal 2026, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.12 to $7.65. CBRE boasts an average earnings surprise of 17%.
Additionally, CBRE's earnings are expected to grow 19.9% for the current fiscal year.
Reveal Winning StocksUnlock all of our powerful research, tools and analysis, including the Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. You'll quickly identify which stocks to buy, hold and sell, and target today's hottest industries, to help improve the performance of your portfolio. Gain full access now >>
As commercial real estate markets evolve, choosing between a global titan like CBRE Group (CBRE +2.08%) and a faster-growing challenger like Newmark Group (NMRK +1.51%) is a key decision for your portfolio.
CBRE provides massive scale and international reach, while Newmark offers agility and higher growth rates. Both companies facilitate property sales, leasing, and management, making them central to the global real estate landscape.
The case for CBRECBRE sells a wide range of services including property management, investment management, and critical infrastructure services. It operates within the commercial real estate investing industry to serve clients in over 100 countries. The company supports nearly 90 of the Fortune 100 and focuses on global scale to attract institutional investors.
In its 2025 fiscal year (FY), revenue reached nearly $40.6 billion, representing growth of 13.4% compared to the previous year. Net income for the period was $1.3 billion, resulting in a net margin of 3.2%. This performance reflects a steady increase from the $35.8 billion in revenue recorded during the prior fiscal year.
As of its December 2025 balance sheet, the debt-to-equity ratio was 1.1x, which measures total debt against shareholder equity. The current ratio, comparing short-term assets to liabilities, was 1.1x. Free cash flow, the cash remaining after capital expenditures, reached $1.2 billion for the year.
The case for NewmarkNewmark operates as a commercial real estate advisor with 175 offices worldwide. It serves institutional investors and global corporations across established and emerging markets on four continents. The company utilizes 9,300 professionals to deliver customized advisory services in a competitive market.
During FY 2025, revenue grew by 20.3% to reach $3.3 billion. The company reported a net income of $126.2 million for that fiscal year. Its net margin was 3.8%, which was an improvement over the 2.2% net margin reported in FY 2024.
Based on the December 2025 balance sheet, Newmark maintains a current ratio of 2.2x and a debt-to-equity ratio of 1.1x. Free cash flow for the year was $142.6 million. Note that stock-based compensation represented 164% of operating cash flow, meaning reported cash generation is heavily inflated by this non-cash add-back.
Risk profile comparisonCBRE faces significant macroeconomic risks, as property activity often drops when interest rates rise. The company also depends on maintaining approvals with agencies like Fannie Mae and Freddie Mac. Furthermore, it must compete with firms like Jones Lang LaSalle and adapt to technological disruptions from artificial intelligence.
Newmark is highly sensitive to the broader economy and transaction volumes. It faces intense competition from larger players including CBRE Group. Additionally, the company relies heavily on government-sponsored entities for its loan servicing business.
Valuation comparisonNewmark appears to be cheaper given its lower Forward P/E and P/S ratio, which compare stock price to future earnings estimates and revenue respectively.
MetricCBRENewmarkSector BenchmarkForward P/E17.6x7.8x33.3xP/S ratio1.0x0.7xn/aSector benchmark uses the SPDR XLRE sector ETF. Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
Commercial real estate has experienced plenty of ups and downs in recent years with the rise in hybrid and remote work models after the COVID-19 pandemic, and now the arrival of artificial intelligence raising questions about how that will impact the sector as job losses to AI may reduce demand. Even so, both CBRE Group and Newmark Group are seeing sales growth, suggesting their businesses continue to expand amidst headwinds such as interest rates showing no signs of a reduction.
CBRE is a giant in the industry, with revenue that’s more than ten times larger than Newmark. However, its stock plunged in February after fourth-quarter net income fell 15% year over year to $416 million due to one-time charges related to a pension plan buyout. Shares continued to fall, eventually hitting a 52-week low of $121.69 on June 1. This creates a potential opportunity to pick up shares at a discount.
Newmark is showing impressive sales growth. Not only did revenue rise 20.3% year over year in FY 2025, in Q1, that growth accelerated to 27.2% as it delivered $846.5 million in sales. In addition, the company pays a dividend yielding a solid 1.6%. CBRE does not pay a dividend.
Considering Newmark’s lower valuation, higher sales growth, and dividend income, it is the better stock to buy over CBRE at this time.
, /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities fraud class action has been filed in the United States District Court for the District of Arizona on behalf of investors who purchased or acquired shares of Verra Mobility Corporation ("Verra" or the "Company") (NASDAQ: VRRM) between February 24, 2026, to May 26, 2026, inclusive.
Investors seeking to serve as lead plaintiff must file a motion by August 4, 2026.
PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION
According to the filed complaint, Defendants provided positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Verra's relationship with Avis Budget Group ("Avis"), In particular, whether it would be obtaining a contract extension with Avis. Further, the Company minimized concerns that major rent-a-cars could replace Verra with in-house solutions or outsourced alternatives.
On May 26, 2026, Verra issued a press release announcing a termination notice from Avis regarding its contract and accordingly lowered its 2026 full-year financial outlook. A week later, June 1, 2026, the Company announced a sudden and surprising transition of its President and Chief Executive Officer, David Roberts.
Following this news, the price of Verra's common stock declined dramatically. From a closing market price of $13.08 per share on May 26, 2026, Verra's stock price fell to $3.85 per share on May 27, 2026, a decline of about 71%.
Investors who purchased Verra shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for August 4, 2026.
WHY WOLF HALDENSTEIN?
This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.
We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.
There is no cost or obligation to speak with an attorney.
Contact:
Phone: (800) 575-0735 or (212) 545-4774 Email: [email protected] Contact Person: Gregory Stone, Director of Case and Financial Analysis Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
125 speed camera locations expected to be operational by the end of 2026
, /PRNewswire/ -- Verra Mobility Corporation (NASDAQ: VRRM), a leading provider of smart mobility technology solutions, announced today that the Los Angeles City Council formally awarded the company to design, build, operate, and maintain a speed safety program across the city and county of Los Angeles.
Los Angeles City Council selected Verra Mobility to design, build, operate, and maintain a speed safety program at 125 speed camera locations across the city Verra Mobility and the Los Angeles Department of Transportation (LADOT) will commence implementation of speed safety systems at 125 sites along high-injury and crash corridors across the city. Many of these sites will use multiple approaches to reduce speeding in both directions. The locations were carefully selected using data on high-speed driving and speed-related crashes throughout the city.
Los Angeles is part of a six-city pilot program, under Assembly Bill 645, that allows speed safety programs aimed at reducing excessive speeding, saving lives, and improving street safety by changing driver behavior.
"We're proud to partner with the City of Los Angeles to implement the largest speed safety program in the state," said Will Barnow, vice president, Verra Mobility. "These programs are complex and must align with strict legislative requirements, so we are honored that the City put their trust in Verra Mobility. As we've seen in other cities, these programs are highly effective at reducing dangerous driving, and we're excited to get to work to advance our shared goal of safer streets for millions of Angelenos."
As a nationally recognized leader in automated traffic enforcement, Verra Mobility brings proven expertise to speed safety programs already operating in San Francisco and Oakland. Cities across the country have seen speeding drop by as much as 94% where this technology is deployed. Most notably, San Francisco's program was recently credited by residents with driving a 50% decline in traffic fatalities in the past year and an 80% decline in speeding after one year.
In Los Angeles, speeding remains one of the most persistent and preventable causes of traffic deaths. According to the Speed Safety System Impact Report, speeding was a factor in 16% of all fatal and severe crashes in Los Angeles between 2017 and 2021. In 2024 alone, over 300 Angelenos were killed in traffic collisions, with one in five of those deaths attributed to speeding.
As part of the program, Verra Mobility will provide the City solutions aligned with AB 645 legislation to help ensure vigorous data and privacy protections, equitable fines, thoughtful education, and a balanced community approach that will begin immediately. Morgner Construction Management, a Los Angeles minority business enterprise (MBE), is expected to be contracted to perform on-the-ground construction and installation of the cameras.
Verra Mobility has led the industry in California, implementing complex, first-of-its-kind programs: San Francisco was the first speed safety program in the state; Mountain House was the first red-light camera safety program implemented under new legislation, SB 720. Now, the company leads the largest and most expansive automated enforcement program in Los Angeles.
To learn more about speed safety solutions and how they can help communities, visit www.verramobility.com/government/speed-enforcement
About Verra Mobility
Verra Mobility Corporation (NASDAQ: VRRM) is a leading provider of smart mobility technology solutions that make transportation safer, smarter and more connected. The company sits at the center of the mobility ecosystem, bringing together vehicles, hardware, software, data and people to enable safe, efficient solutions for customers globally. Verra Mobility's transportation safety systems and parking management solutions protect lives, improve urban and motorway mobility and support healthier communities. The company also solves complex payment, utilization and compliance challenges for fleet owners and rental car companies. Headquartered in Arizona, Verra Mobility operates in North America, Europe, and Australia. For more information, please visit www.verramobility.com.
Forward Looking Statements
We describe many of the trends and other factors that drive our business and future results in this press release. Such discussions contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward looking statements include statements on our contract to design, build, operate, and maintain a speed safety program across the city and county of Los Angeles, including statements on our ability to provide solutions aligned with AB 645 legislation to help ensure vigorous data and privacy protections, equitable fines, thoughtful education, and a balanced community approach, and expectations on the performance of the on-the-ground construction and installation of the cameras. Forward-looking statements are those that address activities, events, or developments that management intends, expects, projects, believes or anticipates will or may occur in the future. They are based on management's assumptions and assessments in light of past experience and trends, current economic and industry conditions, expected future developments and other relevant factors. They are not guarantees of future performance, and actual results, developments and business decisions may differ significantly from those envisaged by our forward-looking statements. We do not undertake to update or revise any of our forward-looking statements, except as required by applicable securities law. Our forward-looking statements are also subject to material risks and uncertainties that can affect our performance in both the near-and long-term. In addition, no assurance can be given that any plan, initiative, projection, goal, commitment, expectation, or prospect set forth in this press release can or will be achieved. These forward-looking statements should be considered in light of the information included in this press release, our Form 10-K and other filings with the Securities and Exchange Commission. Any forward-looking plans described herein are not final and may be modified or abandoned at any time.
Additional Information
We periodically provide information for investors on our corporate website, www.verramobility.com, and our investor relations website, ir.verramobility.com.
We intend to use our website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD. Accordingly, investors should monitor our website, in addition to following the Company's press releases, SEC filings and public conference calls and webcasts.
Philadelphia, Pennsylvania--(Newsfile Corp. - June 15, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against FS KKR Capital Corp. (NYSE: FSK) ("FS KKR" or the "Company") on behalf of investors who purchased or acquired FS KKR securities during the period from May 8, 2024 through February 25, 2026 (the "Class Period").
Investor Deadline: Investors who purchased or acquired FS KKR securities during the Class Period may, no later than July 6, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
Headquartered in Phila., PA, FS KKR is a private credit firm specializing in debt investments. The Company makes loans to other businesses, and its primary revenue source is interest income on debt investments, as well as other fees and dividends.
The suit alleges that, throughout the Class Period, Defendants failed to disclose to investors that the Company: (1) overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; (2) overstated the valuation of its portfolio investments and/or the effectiveness of the Company's portfolio valuation process; and (3) overstated the durability of its quarterly distribution strategy.
According to the complaint, investors first began to learn the true state of FS KKR on August 6, 2025, when the Company reported second quarter 2025 earnings. On that date, Defendants announced that the Company's net asset value had declined to $21.93 per share, down $1.44 (6%) from the prior quarter, and the total fair value of investments declined $474 million, to $13.6 billion. Further, investments on non-accrual status rose to 3.0% and 5.3% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.1% and 3.5% in the prior quarter.
On this news, share prices fell $1.66 per share, or 8%, to close at $18.58 per share on August 7, 2025.
Then, on February 25, 2026, the Company announced fourth quarter and full year 2025 earnings, revealing net asset value had continued to decline to $20.89, down $1.10 (or 5%) from the prior quarter, and the total fair value of investments fell another $406 million, to $13.0 billion. Investments on non-accrual status again rose to 3.4% and 5.5% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.9% and 5.0% in the prior quarter. The Company also "acknowledge[d] specific challenges" with additional companies and cut its dividend to $0.48 per share (down from $0.70).
On this news, the Company's stock price fell $2.03 per share, or 15%, to close at $11.29 per share on February 26, 2026.
If you are an FS KKR investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267) 764-4865.
About Berger Montague
Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301437
Source: Berger Montague
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Key Takeaways DAVE is among five tech services stocks with double-digit YTD gains despite 2026 macro pressures.TT benefits from HVAC demand, decarbonization efforts, and projected 9.1% revenue growth this year.PRTH expects 20.4% earnings growth, with the consensus earnings estimate up 6% in 60 days. The technology services industry is mature, with demand for services in good shape. The global shift toward digitization creates opportunities in various markets, including 5G and artificial intelligence (AI).
Companies are adopting generative AI, agentic AI, machine learning (ML) and data science faster to gain a competitive advantage. Elevated demand for enterprise software, which is ramping up productivity and improving the decision-making process, is a key catalyst.
However, this space has lost momentum in 2026 due to several macroeconomic concerns and geopolitical conflicts. Despite these headwinds, we have narrowed our search to five technology services stocks with a favorable Zacks Rank that have provided double-digit returns year to date.
These companies are: Trane Technologies plc (TT - Free Report) , Dave Inc. (DAVE - Free Report) , V2X Inc. (VVX - Free Report) , Priority Technology Holdings Inc. (PRTH - Free Report) and Enpro Inc. (NPO - Free Report) . Each of our picks currently carries either a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The chart below shows the price performance of our five picks year to date.
Image Source: Zacks Investment Research
Trane Technologies plcZacks Rank #2 Trane Technologies has benefited from a strong heating, ventilation, and air conditioning market as the demand for customer-centric solutions and government-mandated decarbonization efforts increases. TT’s shareholder-friendly policies boost investor morale, thereby increasing confidence in its business. TT’s healthy liquidity position is positive for investors, driven by the rise in accounts receivable.
Trane Technologies has an expected revenue and earnings growth rate of 9.1% and 13.6%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 0.5% over the last 60 days.
Dave Inc.Zacks Rank #1 Dave provides banking apps to build products in the financial playing field in the United States. DAVE offers Budget, a personal financial management tool that helps members anticipate upcoming transactions and receive notifications by utilizing historical bank account data to identify recurring charges.
DAVE also provides ExtraCash, a form of a discretionary overdraft to bridge liquidity gaps between paychecks, Side Hustle, a job application portal to find supplemental or temporary work and Dave Checking, a digital demand deposit account.
DAVE has an expected revenue and earnings growth rate of 28.8% and 22.7%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 4.6% over the last 30 days.
V2X Inc.Zacks Rank #2 V2X is a provider of critical mission solutions and support to defense clients. VVX delivers a comprehensive suite of integrated solutions across operations and logistics, aerospace, training and technology markets to national security, defense, civilian and international clients.
VVX has an expected revenue and earnings growth rate of 10.3% and 17.6%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 0.5% over the last 30 days.
Priority Technology Holdings Inc.Zacks Rank #1 Priority Technology is a solutions provider in Payments and Banking as a Service operating with customers across its SMB, B2B and Enterprise channels. PRTH operates through three segments: Merchant Solutions, Payables and Treasury Solutions.
PRTH’s purpose-built technology enables clients to collect, store, borrow and send while providing customers acceptance of AP payment applications and Passport financial tools that best optimize their cash flow and maximize working capital.
Priority Technology has an expected revenue and earnings growth rate of 8.5% and 20.4%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 6% over the last 60 days.
Enpro Inc.Zacks Rank #2 Enpro is an industrial technology company focused on critical applications across many end-markets, including semiconductor, photonics, industrial process, aerospace, food, pharma and life sciences.
NPO operates in two segments, Sealing Technologies and Advanced Surface Technologies. NPO offers its products in the United States, Europe, Asia Pacific, and internationally. NPO offers its products under the Garlock, Gylon, Blue-Gard, ONE-UP, Bio-Pro, Tuf-Steel, Detectomer, and LINK-SEAL brand names.
Enpro has an expected revenue and earnings growth rate of 11.6% and 15.6%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 2.9% over the last 60 days.
AutoZone (AZO - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this auto parts retailer have returned -6.2% over the past month versus the Zacks S&P 500 composite's +0.5% change. The Zacks Automotive - Retail and Wholesale - Parts industry, to which AutoZone belongs, has lost 1.7% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, AutoZone is expected to post earnings of $55.27 per share, indicating a change of +13.5% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.3% over the last 30 days.
For the current fiscal year, the consensus earnings estimate of $150.45 points to a change of +3.9% from the prior year. Over the last 30 days, this estimate has changed +1%.
For the next fiscal year, the consensus earnings estimate of $175.69 indicates a change of +16.8% from what AutoZone is expected to report a year ago. Over the past month, the estimate has changed +0.3%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AutoZone is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of AutoZone, the consensus sales estimate of $6.71 billion for the current quarter points to a year-over-year change of +7.5%. The $20.48 billion and $22.02 billion estimates for the current and next fiscal years indicate changes of +8.1% and +7.5%, respectively.
Last Reported Results and Surprise HistoryAutoZone reported revenues of $4.84 billion in the last reported quarter, representing a year-over-year change of +8.4%. EPS of $38.07 for the same period compares with $35.36 a year ago.
Compared to the Zacks Consensus Estimate of $4.86 billion, the reported revenues represent a surprise of -0.45%. The EPS surprise was +5.22%.
Over the last four quarters, AutoZone surpassed consensus EPS estimates two times. The company topped consensus revenue estimates just once over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
AutoZone is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AutoZone. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
TruCan Ultra Lyme-L4 is the first and only 1/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose By combining two injections into one, the vaccine minimizes "pokes" supporting comfortable wellness visits for pets Features proprietary PureFil™ Technology, designed to reduce vaccination reactions associated with unwanted proteini,ii,iii Product expected to begin shipping in the next 30 days , /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) approval of TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient combination vaccines. This milestone marks the introduction of the first and only 1/2 mL combination vaccine designed to protect dogs against both Lyme disease and leptospirosis, two increasingly prevalent threats to canine health.
As an expansion of the TruCan Ultra line, this new 1/2 mL formulation provides the same broad protection as the category-exclusive 1 mL version but in half the volume. This combination formulation allows veterinarians to provide essential protection without the need for multiple injections.
TruCan Ultra Lyme-L4 is engineered with Elanco's proprietary PureFilTM Technology, designed to reduce vaccination reactions associated with unwanted protein, allowing clinicians to support patient comfort without compromising on protection.i,ii,iii
"USDA approval of TruCan Ultra Lyme-L4 is a testament to our commitment to vaccine innovation," said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation. "By offering a low-volume, highly-purified combination vaccine, we are providing veterinarians with a powerful tool to help close critical protection gaps while encouraging a comfortable, low-stress experience."
This approval comes at a critical time for canine wellness as all dogs are at risk for leptospirosis regardless of breed, size, lifestyle, or geographic location.iv Leptospirosis is now recognized as a core vaccine per American Animal Hospital Association (AAHA) guidelines,v meaning all dogs should be vaccinated. Additionally, the risk of Lyme disease is spreading to new geographies; however, recent data show a significant "protection gap," with over 40% of at-risk dogs in endemic states lacking a current Lyme vaccine, despite having received their core vaccines.vi
"Leptospirosis and Lyme disease remain important infectious threats for dogs in the U.S.," says Dr. Jessica Pritchard, Clinical Assistant Professor in Small Animal Internal Medicine at the University of Wisconsin-Madison School of Veterinary Medicine, "Leptospirosis vaccination is now considered core for dogs because the exposure risk exists nationwide, including in suburban and urban environments. Vaccination, along with risk-based lifestyle discussions between veterinarians and pet owners, plays an important role in protecting dogs from these preventable diseases."
TruCan Ultra Lyme vaccines have demonstrated 92.2% efficacy against natural infection in highly endemic areasvii and 100% efficacy in laboratory studies.viii By reducing the number of injections required—one "poke" versus two—the combination vaccine is designed to improve the overall wellness visit for pets, owners and veterinary staff.
This approval follows recent USDA approvals of TruCan Ultra B (Oral), the first 1/2 mL oral Bordetella vaccine, and TruCan Ultra CIV H3N2/H3N8, the only 1/2 mL bivalent canine influenza vaccine. Together, these advancements add to a comprehensive suite of low-volume, highly purified vaccines that allow veterinary teams to tailor immunization protocols to the specific needs of every dog.
TruCan Ultra Lyme-L4 is expected to begin shipping in the next 30 days. To learn more about TruCan Ultra Lyme-L4 visit https://my.elanco.com/us/trucan.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
i Elanco Animal Health. Data on File. REF-29478
ii Franco J, Aryal UK, HogenEsch H, Moore GE. Proteomic analysis of canine vaccines. Am J Vet Res. 2023;84(3):ajvr.22.11.0192. Published 2023 Jan 24. doi:10.2460/ajvr.22.11.0192
iii Ohmori K, Masuda K, Maeda S, et al. IgE reactivity to vaccine components in dogs that developed immediate type allergic reactions after vaccination. Vet Immunol Immunopathol. 2005;104(3–4):249–256. doi:10.1016/j.vetimm.2004.12.003
iv Sykes JE, Francey T, Schuller S, Stoddard RA, Cowgill LD, Moore GE. Updated ACVIM consensus statement on leptospirosis in dogs. J Vet Intern Med. 2023 Nov-Dec;37(6):1966-1982. doi: 10.1111/jvim.16903
v AAHA Guidelines
vi Malter KB, et al. Vaccine 2022
vii Levy SA. Vet Ther 2002
viii Elanco Data on File. REF-04031
Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]
Media Contact: Season Solorio (765) 316-0233 [email protected]
The May Jobs report told a familiar story for investors in healthcare stocks. The sector added 35,200 positions last month, led by ambulatory health services at 25,700 and hospitals at 6,000. What makes this number meaningful is the consistency behind it. Healthcare has averaged roughly 38,000 new jobs per month over the past year, a pace that signals sustained demand for services, not a seasonal blip.
That demand has a direct translation to revenue for the right companies. Ambulatory services are growing because patients are being treated outside hospital walls more often. That benefits outpatient clinics, rehabilitation centers, and home care settings. Hospital hiring reflects a steadily rising inpatient census and procedure volume.
Get UnitedHealth Group alerts:
It’s another reminder that when it comes to macroeconomic data, the real story is almost always in the details. Follow where the jobs are being created, and you find the revenue growth. These three names sit at the intersection of where that growth is actually occurring.
UnitedHealth Group: Leveraging Growth in Healthcare UtilizationUnitedHealth Group Today
UNH
UnitedHealth Group
$407.77 -0.75 (-0.18%)
As of 10:32 AM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$234.60▼
$415.98Dividend Yield2.17%
P/E Ratio30.80
Price Target$407.17
More ambulatory visits and more managed care utilization equal more Optum touchpoints. That's the direct equation for UnitedHealth Group as healthcare employment, and—by extension—insured patient volume, continues to expand.
UnitedHealth Group NYSE: UNH sits at the center of the U.S. healthcare system as both its largest private insurer and one of its largest care delivery platforms. Rising demand for healthcare services flows through the business from multiple directions.
The operational narrative at UNH right now is a turnaround, and the healthcare jobs data provides a secular tailwind. That turnaround showed up in the company’s Q1 2026 results, which marked a period of stabilization after a difficult stretch. Revenue reached $111.7 billion, up 2% year-over-year, with UnitedHealthcare generating $86.3 billion and Optum contributing the remainder.
The medical benefit ratio improved to 83.9% from 84.8% a year ago, reflecting better cost management and reserve development. It’s further evidence that the medical cost pressures that plagued the managed care sector are beginning to normalize. To support that idea, management raised its full-year 2026 adjusted earnings per share (EPS) guidance to above $18.25 per share.
Optum Health, which runs value-based care practices and home health operations, including the Amedisys platform it acquired in 2025, directly benefits as the ambulatory workforce expands. More clinicians in the field means more capacity to serve more patients under value-based contracts, where utilization efficiency drives margins.
At 22x forward earnings, UNH is still trading at a slight premium to its historic average, but the valuation is getting better. Several analysts have raised their consensus price target well above the consensus price target of $407.17.
HCA Healthcare: A Direct Play on Rising Hospital DemandWhen hospitals add jobs, they're adding capacity, which gets filled by patients. HCA Healthcare NYSE: HCA, the largest hospital operator in the United States, is about as direct a connection between healthcare employment trends and revenue as it gets. HCA's network currently spans 189 hospitals and approximately 2,600 ambulatory sites, giving it direct exposure to both inpatient and ambulatory demand.
HCA Healthcare Today
HCA
HCA Healthcare
$389.45 +2.27 (+0.59%)
As of 10:32 AM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$330.00▼
$556.52Dividend Yield0.80%
P/E Ratio13.39
Price Target$506.14
The company’s Q1 2026 earnings report confirmed the volume picture remains intact. Revenue reached $19.1 billion, up 4.3% year-over-year. Same-facility admissions grew 0.9%, and same-facility equivalent admissions, which include outpatient procedures, increased 1.3%. Revenue per equivalent admission rose 3.1%, driven by a favorable payer mix and negotiated commercial rate increases. Operating cash flow strengthened to $2 billion, a 22% jump from the prior-year quarter.
HCA Healthcare continues to invest in capacity, deploying $1.1 billion in capital expenditures during Q1 while simultaneously repurchasing $1.6 billion in shares. Yet, HCA is down over 16% in 2026 and well off its all-time high from February. Analysts have a consensus price target of $506.14, which is a gain of about 30% from its price as of this writing.
Encompass Health (EHC): The Post-Acute Play on the Outpatient ShiftThe 25,700 ambulatory jobs added in May aren't just showing up at urgent care clinics. A significant portion reflects the growing demand for post-acute and rehabilitation care—patients discharged from hospitals who need structured recovery before returning home. That's the core business of Encompass Health NYSE: EHC, the largest owner and operator of inpatient rehabilitation hospitals in the United States.
Encompass Health Today
EHC
Encompass Health
$100.06 -1.41 (-1.39%)
As of 10:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$92.77▼
$127.99Dividend Yield0.76%
P/E Ratio16.71
Price Target$143.86
The company’s Q1 2026 earnings report was among the best in the company's recent history. Revenue grew 9% year-over-year to $1.59 billion. Adjusted EBITDA climbed 11.2%, and adjusted EPS surged 16.8%. Management raised full-year 2026 revenue guidance to a range of $6.375 billion to $6.47 billion. The discharge-to-community rate improved 50 basis points to 84.5%, and nurse turnover hit its lowest level since 2012. That's a tangible labor cost benefit in a sector where staffing has been a persistent headwind.
The demand backdrop is structural. The U.S. population continues to age; inpatient rehabilitation services remain undersupplied relative to demand. Plus, the shift away from skilled nursing facilities toward higher-quality rehabilitation settings creates a direct tailwind for EHC's model. The company is actively expanding, opening seven new hospitals in 2026 and adding 100 to 150 beds to existing facilities.
As of June 11, EHC is down about 4% in 2026. However, analysts give the stock a consensus Buy rating with a $143.86 price target that would be a gain of over 40%.
Should You Invest $1,000 in UnitedHealth Group Right Now?Before you consider UnitedHealth Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list.
While UnitedHealth Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Executive appointments reflect leadership momentum and coordinated investment in growth and people
, /PRNewswire/ -- AMN Healthcare, the leader and innovator in healthcare total talent solutions, today announced the appointments of Kristy Willis as Chief Commercial Officer and Holly Novak as Chief People Officer, both effective June 15. In these roles, Willis and Novak will strengthen the company's executive leadership team as it advances its next phase of growth, innovation, and organizational alignment.
Holly Novak, Chief People Officer, AMN Healthcare Willis will lead a newly integrated commercial function bringing together sales, client accounts, marketing and supplier partnerships to create a growth engine for AMN's leading total talent solutions across both acute and nonacute settings powered by its AI-enabled WorkWise platform. Novak will lead the company's human resources function building on its strong culture to advance AMN Healthcare's people strategy for the future. Together, the appointments reflect a coordinated investment in the capabilities and partnerships that drive market growth and the people and culture that power long-term success.
"Kristy and Holly are exceptional leaders bringing strong expertise and skill to our leadership team in two areas that matter deeply to our future: client leadership and growth and our people," said Cary Grace, President and CEO of AMN Healthcare. "Kristy brings the commercial leadership and execution focus to help us sharpen our market strategy, differentiate our client value proposition and create stronger alignment across the client lifecycle. Holly is a transformative HR leader with the experience and expertise to continue building a place where our team members can thrive and do their best work."
As Chief Commercial Officer, Willis will lead an integrated commercial organization with a primary focus on client growth and market execution. She most recently served as President of PeopleReady, a $1.5 billion national workforce solutions business, part of the TrueBlue portfolio. Through her career, Willis has built successful commercial organizations that align sales strategy, customer experience, and execution at scale, while strengthening go-to-market discipline and driving performance in complex, highly regulated environments.
As Chief People Officer, Novak will lead AMN Healthcare's human resources function and help advance the company's people strategy during a time of growth and innovation. She brings more than 20 years of experience as a people leader and most recently served as Chief People Officer at Jack Henry, a financial technology company. Novak brings deep experience aligning people strategies to business goals and optimizing performance through talent management, succession planning, workforce analytics, and total rewards programs in complex, highly regulated organizations.
"As we continue evolving to meet the needs of our valued clients, clinicians, and team members, we are building an organization that is more connected, more agile, and well equipped to execute with speed and quality," added Grace.
About AMN Healthcare
AMN Healthcare is the leader and innovator in total talent solutions for healthcare, bringing together the people, processes and technology to deliver better care. Through a steadfast partnership approach, we solve the most pressing workforce challenges to enable better clinical outcomes and access to care. In 2025 our healthcare professionals reached more than 13 million patients at more than 2,300 healthcare systems, including 93 percent of the top healthcare systems nationwide. We provide a comprehensive network of quality healthcare professionals and deliver a fully integrated and customizable suite of workforce technologies.
Key Takeaways MXL's Panther storage accelerator SoC gains Tier 1 design wins among cloud and network providers.MXL Panther V delivers 450 Gbps throughput and more than 4x power savings vs software compression.MXL and Los Alamos National Laboratory enable hardware-accelerated OpenZFS via Panther DPUSM integration. MaxLinear (MXL - Free Report) continues to build momentum with its Panther hardware storage accelerator System-on-Chip family within its infrastructure business. The company is seeing growing design win activity among Tier 1 network appliance and cloud service providers. Compared to traditional software compression, Panther achieved significant advantages, including more than 4x improvement in power savings and more efficient utilization of CPUs, CPU cores and AI accelerators.
At the Future of Memory and Storage SMS 2025 conference in Santa Clara, CA, MaxLinear announced its Panther V storage accelerator, which delivers ultra-low latency, 450 gigabits per second throughput and PCIe Gen 5 connectivity. The company started sampling Panther 5 to leading customers and our partners, including Advanced Micro Devices or AMD. Based on current engagement, management expects storage accelerator revenues to at least double in 2026 compared to 2025.
As a recent development, MaxLinear and Los Alamos National Laboratory are partnering to enable hardware-accelerated OpenZFS File System storage for large-scale, high-performance computing (HPC) environments. The effort brings togetherMaxLinear’s Panther Storage Accelerator and LANL’s advancement in Direct I/O and Z.I.A (ZFS Interface for Accelerators) framework, developed to accelerate performance for the ZFS-using community.
Through this collaboration, Panther is integrated with ZFS as a Data Processing Unit Services Module provider, enabling inline hardware acceleration of select CPU-intensive operations such as data compression and checksum generation, to increase storage capacity, improve file I/O performance and reduce host CPU utilization.
According to the company, the combined hardware-software approach preserves ZFS ordering, consistency and data integrity guarantees while allowing efficient compute offload and scalable acceleration.
News From MXL PeersBroadcom Inc. (AVGO - Free Report) has announced the establishment of the AI XPV Platform with Apollo and Blackstone's Credit & Insurance Business as initial anchor investors. The Platform is designed to enable more than 20 gigawatts in compute capacity using Broadcom's XPUs and networking solutions customized for leading frontier AI labs, including Anthropic and OpenAI, through 2028. The Platform has launched with an initial transaction of $35 billion to facilitate Anthropic's previously announced capacity expansion of more than 1 gigawatt of compute infrastructure expected to be deployed in Fluidstack-based sites starting in mid-2026.
Skyworks Solutions, Inc. (SWKS - Free Report) unveiled its new Si829x isolated safety gate driver for electric vehicle traction inverters and other electrified systems, including eTrucking, industrial motor drives and emerging mobility platforms, at PCIM 2026. In contrast to the conventional voltage-mode gate drivers, the Si829x uses ProVCD, Skyworks’ second-generation variable current drive, with high-resolution gate waveform shaping and cycle-by-cycle control through a digital interface.
MXL Stock Performance, Valuation & Estimates
Over the past three months, MaxLinear shares have surged 387.6% compared with the industry’s 50% growth.
Image Source: Zacks Investment Research
MXL shares are trading at a forward, five-year Price/Sales (P/S) of 10.65X compared with its 2.81X median and the industry average of 10.62X.
Image Source: Zacks Investment Research
Here’s how estimates for MaxLinear’s 2026 and 2027 earnings have been shaping up for the past 60 days.
Image Source: Zacks Investment Research
MaxLinear currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Considering buying ICUI stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
June 15, 2026 09:15 ET | Source: Goosehead Insurance, Inc.
WESTLAKE, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- Goosehead Insurance, Inc. (“Goosehead” or the “Company”) (NASDAQ: GSHD), a rapidly growing, independent personal lines insurance agency, today announced the appointment of Eben Hewitt as Chief Technology Officer.
Hewitt joins Goosehead from Hyatt Corporation, where he served as Global Chief Information Officer, overseeing engineering, data and AI, infrastructure, cybersecurity, technology operations, and enterprise applications. Prior to Hyatt, he held senior technology leadership positions at Sabre Hospitality Solutions, Choice Hotels, and O'Reilly Media. Throughout his career, Hewitt has built and scaled global technology organizations and developed award-winning software products serving millions of users.
As CTO, Hewitt will lead Goosehead's technology strategy, including the expansion of AI-powered capabilities, data and analytics platforms, and the continued evolution of Digital Agent 2.0.
"The successful completion of the first phase of Digital Agent 2.0 established a powerful foundation for the future of our platform. As we enter the next phase of innovation, we see a significant opportunity to accelerate our strategic use of AI, data, and automation to further transform the personal lines industry. Eben's experience leading world-class global technology organizations and deploying AI-driven capabilities at scale will help accelerate our development of the most intelligent, efficient, and client-centric platform in the industry," said Mark Miller, Chief Executive Officer of Goosehead.
"I am excited to join Goosehead and help advance the company's technology vision," said Hewitt. "Goosehead has built an industry-leading platform and a culture of innovation. I look forward to helping advance the company's AI and technology strategy to empower agents, enhance client experiences, and support accelerated growth.”
About Goosehead
Goosehead (NASDAQ: GSHD) is a rapidly growing and innovative independent personal lines insurance agency that distributes its products and services through corporate and franchise locations throughout the United States. Goosehead was founded on the premise that the consumer should be at the center of our universe and that everything we do should be directed at providing extraordinary value by offering broad product choice and a world-class service experience. Goosehead represents over 200 insurance companies that underwrite personal and commercial lines. For more information, please visit goosehead.com or goosehead.com/become-a-franchisee.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements regarding the anticipated benefits of the Company's AI, data, and automation initiatives; the expected impact of new executive leadership on the Company's technology strategy; and the potential to accelerate growth in the personal lines insurance industry.
Forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially, including, but not limited to, the failure to successfully implement or realize the anticipated benefits of AI and automation initiatives, including reliance on third-party AI tools and data platforms; the failure to execute on the Company's technology and platform strategy; competitive developments in insurance technology and conditions impacting insurance carriers or other parties with which the Company does business; and those described in the Company’s filings with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated.
You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made. Goosehead does not undertake any obligation to update them except as may be required by applicable law.
Contacts
Investor Contacts:
Maddie Middleton
Goosehead Insurance - Senior Director of Investor Relations
Email: [email protected]; [email protected];
PRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Bob Davis, executive vice president and president Tissue Reconstruction will present at the 2026 Truist Securities MedTech Conference on June 16, 2026 at 3:00pm ET.
A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study
Single infusion of LB2501 generated dose-dependent in vivo CAR-T expansion without lymphodepletion
No dose-limiting toxicities, serious adverse events, ICANS, or deaths were reported; infusion-related reactions and CRS were Grade 1–2, and none required glucocorticoids for CRS management
Additional translational data showed rapid vector clearance, polyclonal vector integration, and no evidence of non-specific transduction
Proof-of-concept progress demonstrates leadership in next-generation cell therapies, with results presented in a late-breaking session at EHA 2026
BRIDGEWATER, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).
In the ongoing Phase 1 study, a single infusion of LB2501 generated dose-dependent in vivo CAR-T expansion without lymphodepletion. At the higher dose level (DL2), LB2501 achieved a 100% objective response rate (ORR) (6/6) and an 83.3% complete response rate (CR) (5/6), with all responses ongoing at the time of data cutoff. LB2501 also showed a favorable safety profile, with no dose-limiting toxicities (DLTs), serious adverse events (SAEs), immune effector cell-associated neurotoxicity syndrome (ICANS), or deaths reported.
“In vivo CAR-T represents a compelling frontier in cell therapy, enabling the generation of CAR-T cells directly within the patient, with the potential to simplify treatment and expand access over time,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “LB2501 is our step toward realizing that vision and reflects further progress toward our goal of leading the future of cell therapy. Backed by the commercial and scientific foundation we have built with CARVYKTI, we are well-positioned to advance this next generation of CAR-T delivery. These early data, with deep responses from a single infusion across patients, give us confidence in the path ahead.”
LB2501 Demonstrates In Vivo CAR-T Generation and Early Clinical Activity
In an ongoing Phase 1 study, 12 patients with R/R B-NHL received LB2501 across two dose levels, DL1 (n=6) and DL2 (n=6). Patients had received a median of three prior lines of therapy, and 58.3% were refractory to their most recent treatment. The open-label, multi-center, dose-escalation study is evaluating safety, recommended Phase 2 dose, pharmacokinetics, and preliminary efficacy in adults with R/R B-NHL. The study was conducted without lymphodepletion.
At DL2, LB2501 achieved a 100% ORR (6/6) and an 83.3% CR rate (5/6), with responses observed across patients with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Across both dose levels, the ORR was 50.0% (6/12), and the CR rate was 41.7% (5/12). At the time of data cutoff, all responses at DL2 were ongoing.
LB2501 showed a favorable safety profile. No DLTs, SAEs, ICANS, or deaths were reported. Infusion-related reactions (IRR) and cytokine release syndrome (CRS) were the most common adverse events of special interest and were all Grade 1–2. Infusion-related reactions occurred in 75.0% (9/12) of patients overall, with a median onset of 1.4 hours after infusion and a median recovery time of 18.6 hours. CRS occurred in 66.7% (8/12) of patients overall, with a median onset at Day 11 and a median duration of 4.5 days. IRR and CRS were all Grade 1–2, no patients required glucocorticoids for CRS management. Four patients received tocilizumab.
Pharmacokinetic analyses showed dose-dependent in vivo CAR-T expansion in 100% (6/6) of patients at DL2 and 83% (5/6) of patients at DL1. CAR-T cells remained detectable in peripheral blood for up to 116 days. Viral copy number in peripheral blood peaked immediately after infusion and decreased to undetectable concentrations within 24 hours.
Additional translational analyses further characterized the in vivo profile of LB2501. No evidence of non-specific transduction was detected in NK cells or other non-T/B/NK lymphocyte populations. Vector integrations were highly polyclonal and diverse. These findings support proof-of-concept for in vivo T-cell engineering, with polyclonal vector integration and rapid vector clearance.
“These early clinical findings are encouraging in a heavily pretreated relapsed or refractory B-cell non-Hodgkin lymphoma population,” said Lei Fan, M.D., Ph.D., Professor, Doctoral Supervisor, and Administrative Director, Hematology Department, Jiangsu Province Hospital, Nanjing, China. “The responses observed at the higher dose level achieved a 100% objective response rate, together with a favorable safety profile and the absence of lymphodepletion, support further investigation of LB2501 as a novel in vivo CAR-T approach. The additional pharmacokinetic and translational findings presented at EHA further support the feasibility of generating CAR-T cells directly within the patient.” ‡
ABOUT LB2501
LB2501 is an investigational, potential first-in-class CD19/CD20 dual-targeting in vivo CAR-T therapy designed to generate CAR-T cells directly within the patient following a single intravenous infusion. It is being evaluated in an ongoing Phase 1, open-label study (NCT07002112) in patients with relapsed/refractory B-cell malignanciesi to assess safety, tolerability, and preliminary efficacy.[i]
ABOUT B-CELL NON-HODGKIN LYMPHOMA
Non-Hodgkin lymphoma (NHL) is a group of cancers that originate in lymphocytes, a type of white blood cell that plays a key role in the body’s immune system.ii B-cell lymphomas account for approximately 85% of NHL cases and arise from abnormal growth of B lymphocytes (B cells), which are responsible for producing antibodies. These malignancies include a range of subtypes that vary in aggressiveness, from slow-growing to highly aggressive disease.iii
While treatment advances have improved outcomes for some patients, those with relapsed or refractory B-cell NHL, particularly after multiple lines of therapy, often face limited options.
ABOUT LEGEND BIOTECH
With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at https://legendbiotech.com and follow us on X, Instagram, and LinkedIn.
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives, the Phase 1 clinical trial of LB2501, and the potential benefits of LB2501, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, and LB2501’s potential to be first-in-class. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by Legend Biotech’s third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2026. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
‡ Lei Fan, M.D., Ph.D., Professor, Doctoral Supervisor, and Administrative Director, Hematology Department, Jiangsu Province Hospital, Nanjing, China, has provided consulting and advisory services to Legend Biotech; he has not been paid for any media work.
______________________________
i ClinicalTrials.Gov. The CD19/ CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies. https://clinicaltrials.gov/study/NCT07002112. Accessed May 2026
ii American Cancer Society. “What Is Non-Hodgkin Lymphoma?”. Available at: https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/what-is-non-hodgkin-lymphoma.html.Accessed May 2026.
iii American Cancer Society. “Types of B-cell Lymphoma”. Available at: https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/b-cell-lymphoma.html. Accessed May 2026.
Investors seeking reliable income often look to healthcare properties for stability, which makes the choice between Community Healthcare Trust (CHCT 0.22%) and Sabra Health Care REIT (SBRA 0.40%) a compelling comparison for 2026.
Community Healthcare Trust carves out a niche by focusing on smaller outpatient facilities, whereas Sabra Health Care REIT operates as an industry giant with a wide reaching portfolio of long-term care beds. Both companies offer unique advantages depending on your preference for specialized niche properties or broad scale within the medical facility landscape.
Community Healthcare Trust targets a specific niche within the healthcare sector by acquiring outpatient facilities in non-urban and suburban markets. The portfolio consists of nearly 198 properties across 35 states, serving a variety of medical providers such as behavioral health and specialty clinics. While the company maintains a broad tenant base, its largest rent contributors include US HealthVest at roughly 7.3% and Lifepoint Health at approximately 6.4% of annualized rent.
In FY 2025, revenue reached approximately $121.2 million, which represents a growth rate of nearly 4.7% compared to the prior year. The company reported a net income of roughly $5.1 million during this period, yielding a net margin of about 4.2%. This return to profitability is notable after the business experienced a net loss in the previous fiscal year, indicating a stabilization in the company's operating results for its investors.
As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 1.2x. This metric measures the company's total debt relative to shareholder equity, indicating how much the company relies on borrowed funds to finance its property acquisitions. The current ratio, which tracks the ability to pay short-term obligations with liquid assets, is roughly 0.2x, while free cash flow reached close to $56.4 million in FY 2025.
The case for Sabra Health Care REITSabra Health Care REIT operates as a large-scale landlord with a primary focus on senior housing, skilled nursing, and behavioral health facilities. Its massive portfolio includes close to 361 properties and more than 36,412 beds across the United States and Canada. This broad diversification across different types of care facilities is a central pillar for those interested in real estate investing within the medical sector.
During FY 2025, revenue reached nearly $774.6 million, marking a growth rate of approximately 10.2% over the prior year. The company achieved a net income of roughly $155.6 million, resulting in a net margin of close to 20.1% for the year. This level of profitability highlights the company's ability to generate significant earnings from its long term lease agreements and managed senior housing communities during a period of rising demand.
The balance sheet from December 2025 shows a debt-to-equity ratio of about 0.9x. This ratio shows that the company uses roughly $0.90 in debt for every dollar of equity, which helps investors understand the company's financial leverage and capital structure. The current ratio is roughly 0.6x, and free cash flow, which represents cash from operations minus capital expenditures, was approximately $348.6 million for the fiscal year.
Risk profile comparisonCommunity Healthcare Trust faces risks related to its concentration in the healthcare industry, which makes it sensitive to changes in medical reimbursement and regulation. Approximately 26.7% of its annualized rent comes from properties in Texas and Florida, creating significant exposure to regional economic shifts or natural disasters. The company also deals with tenant financial stability risks, where the bankruptcy of a major provider could lead to lease non-renewals or a sudden loss of rental income.
Sabra Health Care REIT is sensitive to rising interest rates, which can increase the cost of its debt and impact the overall stock price. The company faces operational risks in its senior housing managed communities, including labor shortages and rising wages that can eat into profits. It also competes for property acquisitions and tenants with much larger peers like Welltower and Ventas, which may have greater financial resources to outbid it for prime real estate.
Valuation comparisonSabra Health Care REIT appears more attractively priced based on future earnings estimates, while Community Healthcare Trust trades at a lower multiple relative to its current sales levels.
MetricCommunity Healthcare TrustSabra Health Care REITSector BenchmarkForward P/E37.2x27.4x32.2xP/S ratio4.1x6.0xn/aSector benchmark uses the SPDR XLRE sector ETF. Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
Which stock would I buy in 2026?Choosing between Sabra Health Care and Community Healthcare Trust may ultimately come down to what you believe the future looks like for senior care. America is greying, as the massive baby boomer generation ages. Projections indicate that by 2035, adults 65 and older will number 77 million, surpassing the number of children under age 18 (76.5 million) for the first time in U.S. history. By 2060, nearly 25% of the population is expected to be over age 65. This narrative alone is a strong case for investing in senior care facilities and adjacent companies like Sabra.
Sabra hit a losing streak in June, dropping 15% and losing almost $800 million in market cap on investor fears about persistently high interest rates and share dilution from an at-the-market equity program, but analysts following the stock maintain their hold or buy ratings, with none recommending selling at this time. Indeed, with concerns already priced in, now may be the time to dig into Sabra stock, which has already begun to rebound. Its 6.41% dividend yield may also be a nice incentive to wait out the volatility.
Key Takeaways Flight testing helps Archer evaluate propulsion, flight controls and overall system integration.ACHR uses test-flight data to refine aircraft designs and improve operational reliability.Expanding flight tests supports certification readiness and builds operational experience for deployment. Archer Aviation Inc. (ACHR - Free Report) continues to advance its aircraft development efforts through an expanding flight-test program. Flight testing remains one of the most important stages in the development process, allowing the company to evaluate aircraft performance, validate system functionality and generate operational data that can support future certification activities.
A key benefit of flight testing is the ability to assess how various aircraft systems perform under real-world operating conditions. Through ongoing test flights, Archer can gather information related to aircraft handling, propulsion performance, flight controls and overall system integration. These insights help the company refine designs, improve operational reliability and support future development milestones.
The flight-test program also plays an important role in reducing technical risk as Archer progresses toward commercialization. Data collected from testing activities can be used to verify engineering assumptions, identify areas for improvement and strengthen confidence in aircraft performance. Continued testing supports a more structured development process while helping the company prepare for future operational requirements.
As Archer expands its testing activities, it is building valuable experience across engineering, operations and aircraft validation. This growing body of flight data and operational knowledge could support future certification efforts and strengthen the company's readiness for commercial deployment. Continued progress in flight testing remains an important step in Archer's broader strategy to bring advanced aircraft technologies to market.
Companies Advancing Flight-Test ProgramsAs next-generation aircraft development continues across the aerospace sector, companies are expanding flight-test activities to validate performance and support certification objectives. Companies like Joby Aviation, Inc. (JOBY - Free Report) and Textron Inc. (TXT - Free Report) are also advancing aircraft testing programs.
Joby Aviation continues conducting flight-testing activities for its electric aircraft platform as it progresses through development and certification-related milestones.
Textron supports aircraft development through flight-test programs across multiple aviation platforms, helping validate performance, safety and operational capabilities.
Earnings Estimates for ACHR StockThe Zacks Consensus Estimate for 2026 and 2027 earnings per share suggests a year-over-year decline of 61.90% and growth of 7.51%, respectively.
Image Source: Zacks Investment Research
ACHR Stock Trading at a DiscountArcher Aviation is trading at a discount relative to the industry, with a trailing 12-month price-to-book of 1.85X compared with the industry average of 5.95X.
Image Source: Zacks Investment Research
ACHR Stock Price PerformanceOver the past three months, ACHR shares have fallen 17% compared with the industry’s 6.5% decline.
Image Source: Zacks Investment Research
ACHR’s Zacks RankArcher Aviation currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Key Takeaways U.S. stocks are set for a firmer start as hopes of a U.S.-Iran peace deal lift market sentiment.The screen targets stocks beating the S&P 500 over 12 weeks, four weeks and one week.PLGO, GCO, DAVE, NUE and ARW passed the screen with positive estimate revisions and strong price gains. U.S. stocks look set to begin the week on a firmer note as hopes of a U.S.-Iran peace deal ease a major source of market anxiety. Stock futures moved higher, oil prices fell, and markets rallied following reports of progress in reopening the Strait of Hormuz. Lower crude prices could help cool inflation worries, giving investors more confidence ahead of the Federal Reserve’s policy decision.
The tone is not risk-free, since details of the agreement still need to be signed, and energy flows may take time to normalize. Even so, the backdrop has turned mildly bullish. Stronger interest in technology and innovation-led names also points to improving confidence. In this setting, relative price strength remains a useful strategy. Stocks already outperforming may attract fresh buying as sentiment improves.
At this stage, investors would be wise to consider companies such as Pelagos Insurance Capital Limited (PLGO - Free Report) , Genesco Inc. (GCO - Free Report) , Dave Inc. (DAVE - Free Report) , Nucor Corporation (NUE - Free Report) and Arrow Electronics (ARW - Free Report) .
Relative Price Strength Strategy
Investors generally gauge a stock’s potential returns by examining earnings growth and valuation multiples. At the same time, it’s essential to measure the performance of such a stock relative to its industry, peers, or an appropriate benchmark.
If you see that a stock is underperforming on fundamental factors, it would be prudent to move on and find a better alternative. However, those outperforming their respective sectors in terms of price should be selected because they stand a better chance of providing considerable returns.
Then again, it is imperative that you determine whether or not an investment has relevant upside potential when considering stocks with significant relative price strength. Stocks delivering better than the S&P 500 for 1 to 3 months, at least, and having solid fundamentals, indicate room for growth and the best way to go about this strategy.
Finally, it is crucial to find out whether analysts are optimistic about the upcoming earnings of these companies. In order to do this, we have added positive estimate revisions for the current quarter’s (Q1) earnings to our screen. When a stock undergoes an upward revision, it leads to additional price gains.
Screening Parameters
Relative % Price change – 12 weeks greater than 0
Relative % Price change – 4 weeks greater than 0
Relative % Price change – 1 week greater than 0
(We have considered those stocks that have been outperforming the S&P 500 over the last 12 weeks, four weeks and one week.)
% Change (Q1) Est. over 4 Weeks greater than 0: Positive current-quarter estimate revisions over the last four weeks.
Zacks Rank equal to 1: Only Zacks Rank #1 (Strong Buy) stocks — that have returned more than 26% annually over the last 26 years and surpassed the S&P 500 in 23 of the last 26 years — can get through. You can see the complete list of today’s Zacks #1 Rank stocks here.
Current Price greater than or equal to $5 and Average 20-day Volume greater than or equal to 50,000: A minimum price of $5 is a good standard to screen low-priced stocks, while a high trading volume would imply adequate liquidity.
VGM Score less than or equal to B:Our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 or 2 (Buy), offer the best upside potential.
Here are five of the 14 stocks that made it through the screen:
Pelagos Insurance Capital: Pelagos Insurance Capital is a specialty insurance and reinsurance company focused on strategic capital allocation and careful risk selection. Backed by strong ratings, diversified underwriting partners and solid capital, it aims to build long-term value. Over the past 60 days, the Zacks Consensus Estimate for the company’s 2026 earnings has moved up 14.9%. PLGO has a VGM Score of B.
Pelagos Insurance Capital beat the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other. It has a trailing four-quarter earnings surprise of roughly 53.6%, on average. PLGO shares have gained 41.5% in a year.
Genesco: Genesco is a footwear-focused retailer bringing style-led brands like Journeys, Schuh, Johnston & Murphy and Little Burgundy to customers. It blends curated products, distinct brand stories, digital growth and strong teams to build loyalty. The Zacks Consensus Estimate for Genesco’s fiscal 2027 earnings indicates 55.2% growth. GCO has a VGM Score of B.
The firm has a market capitalization of around $472 million. Over the past 60 days, the Zacks Consensus Estimate for Genesco’s fiscal 2027 earnings has gone up 4.7%. GCO’s shares have surged 93.6% in a year.
Dave: It is a digital banking platform helping underserved users manage money with ease. DAVE’s tools include budgeting support, interest-free cash advances, side income opportunities, and a modern checking account — all designed to boost financial health. The Zacks Consensus Estimate for 2026 earnings of the company indicates 22.7% growth. DAVE has a VGM Score of B.
Over the past 60 days, the Zacks Consensus Estimate for DAVE’s 2026 earnings has moved up 11.1%. The company has a market capitalization of $3.7 billion. DAVE shares have gone up 32.4% in a year.
Nucor: Nucor is a leading producer of structural steel, steel bars, steel joists, steel deck and cold finished bars in the United States. The Zacks Consensus Estimate for 2026 earnings of Nucor indicates 103.8% growth. NUE has a VGM Score of B.
Over the past 60 days, the Zacks Consensus Estimate for Nucor’s 2026 earnings has moved up 33.4%. The company has a market capitalization of $69.7 billion. NUE shares have gone up 119% in a year.
Arrow Electronics: The company is one of the world’s largest distributors of electronic components and enterprise computing products. Over the past 60 days, the Zacks Consensus Estimate for Arrow Electronics’ 2026 earnings has moved up 40.9%. ARW has a VGM Score of B.
Arrow Electronics beat the Zacks Consensus Estimate for earnings in each of the last four quarters. It has a trailing four-quarter earnings surprise of roughly 33.7%, on average. ARW shares have gained 81.7% in a year.
CENTENNIAL, Colo.--(BUSINESS WIRE)--Global technology solutions provider Arrow Electronics today announced it has earned the Frontier Distributor designation within the Microsoft AI Cloud Partner Program.
"Microsoft’s Frontier Distributor designation reflects the investments we continue to make in cloud, AI and technical enablement across our channel ecosystem." - Sophie Daval, Director, Hyperscalers, Global ArrowSphere, Arrow Electronics
Share The Frontier Distributor designation recognizes distributors that consistently enable channel partner success through scale, readiness and execution. It reflects strong operational maturity, channel partner enablement capabilities and measurable customer impact.
This achievement reflects Arrow’s role in supporting channel partners and customers with the infrastructure, programs and services required to deliver outcomes using Microsoft technologies.
Arrow supports channel partners through ArrowSphere, its digital distribution platform, alongside regional technical, commercial and enablement teams across EMEA and North America. In November 2025, Microsoft named Arrow its 2025 Distribution Partner of the Year, recognizing ArrowSphere AI offerings, including ArrowSphere Assistant. The Frontier Distributor designation further strengthens Arrow’s ability to help channel partners build, deploy and scale Microsoft cloud and AI solutions across multiple markets and industries.
Sophie Daval, director, hyperscalers, global ArrowSphere at Arrow’s enterprise computing solutions business, said, “Microsoft’s Frontier Distributor designation reflects the investments we continue to make in cloud, AI and technical enablement across our channel ecosystem. Following our recognition as Microsoft’s 2025 Distribution Partner of the Year, this designation further reinforces our ability to help channel partners simplify cloud adoption, support AI deployments and build scalable services around Microsoft technologies.”
“The Frontier Distributor designation recognizes leading Cloud Solution Provider distributors, such as Arrow, who help partners accelerate cloud solutions more effectively,” said Alex Zagury, CVP, global channel sales, Microsoft. “This recognition reflects their ability to drive differentiation at scale and deliver meaningful value to small and medium-sized businesses.”
About Arrow Electronics
Arrow Electronics (NYSE:ARW) sources and engineers technology solutions for thousands of leading manufacturers and service providers. With 2025 sales of $31 billion, Arrow’s portfolio enables technology across major industries and markets. Learn more at arrow.com.
PORTSMOUTH, N.H.--(BUSINESS WIRE)--Iron Mountain Incorporated (NYSE: IRM) (the "Company"), a global leader in information management services, today announced a proposed offering of $1.0 billion aggregate principal amount of its Senior Notes due 2035 (the “Notes”). The Notes will initially be fully and unconditionally guaranteed by the Company's subsidiaries that are obligors under each series of its existing notes. The Company intends to use the net proceeds from the offering of the Notes to r.
$1.5 billion-asset bank will utilize Jack Henry's trifecta of core, payments, and digital solutions to position for growth
, /PRNewswire/ -- Jack Henry® (Nasdaq: JKHY) announced today that CorTrust Bank has selected Jack Henry to implement a flexible, open platform that will drive operational efficiency and support long-term growth. By improving efficiency and increasing assets per employee, the bank is positioned to reinvest in its local communities and be the financial provider of choice across every stage of customers' personal and business journeys.
Founded in 1930 in Mitchell, South Dakota, CorTrust Bank has $1.5 billion in assets, 37 locations, and over 250 employees across South Dakota and Minnesota. The bank's offering varies by market, from agricultural and retail banking in smaller communities to commercial-focused services in larger metro areas, including the Twin Cities.
As CorTrust Bank evaluated its long-term technology strategy, flexibility, integration capabilities, and customer experience were key priorities. Moving to Jack Henry's core processing platform will automate manual processes and streamline workflows, allowing employees to spend less time on operational tasks and more time serving customers. The Banno Digital Platform™ will deliver a more modern and customizable digital banking experience across both retail and business accounts. And, through Banno, JHA Card Processing Solutions™ (CPS) will unify debit and credit card services, creating a more consistent experience across channels and devices.
"We were seeing customers expect more personalized and connected banking experiences, and we knew we needed technology that would allow us keep pace," said Jack Hopkins, President and CEO of CorTrust Bank. "What stood out about Jack Henry was how seamlessly the platform works together. Everything from core to digital banking and card services is much more connected, creating a better experience for customers and allowing our employees to focus less on cumbersome work and more on serving our communities."
Jack Henry's open ecosystem, which offers integrations with more than 1,000 third-party fintechs, also played an important role in CorTrust Bank's decision. "Banking is evolving quickly, and no single provider can deliver every solution customers expect today," Hopkins added. "We wanted the flexibility to bring in the products and services that make the most sense for our customers and communities. Jack Henry's open and customizable approach really stood out compared to what we had experienced in the past."
"For nearly 100 years, CorTrust Bank has combined community banking values with a forward-looking approach to growth," said Jonathan Baltzell, President of Bank Solutions at Jack Henry. "Our platform gives the bank the flexibility, efficiency, and integration capabilities needed to continue evolving alongside customer expectations."
About Jack Henry & Associates, Inc.®
Jack Henry® (Nasdaq: JKHY) is a well-rounded financial technology company that strengthens connections between financial institutions and the people and businesses they serve. We are an S&P 500 company that prioritizes openness, collaboration, and user centricity – offering banks and credit unions a vibrant ecosystem of internally developed modern capabilities as well as the ability to integrate with leading fintechs. For 50 years, Jack Henry has provided technology solutions to enable clients to innovate faster, strategically differentiate, and successfully compete while serving the evolving needs of their accountholders. We empower approximately 7,400 clients with people-inspired innovation, personal service, and insight-driven solutions that help reduce the barriers to financial health. Additional information is available at www.jackhenry.com.
The semiconductor sector ripped 8.8% in a single week, with the SMH ETF closing at $619.96 on June 12, 2026, reclaiming levels above both Tuesday’s and Friday’s highs after getting hard hit last Friday. The host of Stock Market Today With IBD said the ETF contains a lot of chips that are well into new high territory that really just didn’t stop at all. If you waited for confirmation, confirmation showed up. These are the five names doing the heavy lifting.
1. Kulicke & Soffa (KLIC): The Small-Cap Nobody’s Talking About Start with the name most portfolios don’t own. Kulicke & Soffa (NASDAQ:KLIC) makes the back-end packaging equipment that bonds AI chips together, and the host put it right there in new high territory. The company is raising fiscal-year capex from $12M to $22M specifically to expand its Thermo-Compression Bonding systems toward a $400M annual TCB sales target. That is direct advanced-packaging exposure, sold to the same fabs running NVIDIA and AMD’s hottest silicon.
The Q2 FY26 print, reported May 6, 2026, showed revenue of $242.62 million against $161.99 million the prior year, with non-GAAP EPS swinging to $0.79 from a $0.52 loss. CEO Lester Wong said, “Demand is stronger than anticipated due to both technology and capacity needs across general semiconductor, memory, automotive and industrial end markets.” Guidance for the next quarter calls for revenue near $310M and non-GAAP EPS around $1.00.
The stock added 15% last week and is up 149% year to date at $113.13. The 52-week low was $30.93. The next name is the one institutions are forced to own.
2. Lam Research (LRCX): The Heavyweight Doing the Talking If KLIC is the whisper, Lam Research (NASDAQ:LRCX | LRCX Price Prediction) is the roar. The host called it out by name as looking very strong. Lam sells the deposition and etch tools that every leading-edge fab needs to build HBM stacks and gate-all-around transistors. Every dollar of hyperscaler AI capex eventually walks through a Lam tool.
The March 2026 quarter delivered revenue of $5.84 billion, up 23.8% year over year, with non-GAAP EPS of $1.47 against a $1.36 consensus, the fourth consecutive EPS beat. Operating margin expanded to 35.0%. CEO Tim Archer said, “Lam delivered record revenue and EPS in the March quarter as AI-driven demand reshapes the semiconductor industry.” June quarter guidance points to $6.60 billion in revenue, a sequential acceleration.
Shares jumped 21% last week to $366.81, with a year-to-date gain of 115%. On a 10-year basis, Lam is up 5,013%. The next name is the only company in the world that builds the machine Lam’s customers can’t live without.
3. ASML: The Monopoly There is exactly one supplier of EUV lithography systems on the planet, and ASML (NASDAQ:ASML) is it. No EUV, no advanced node. No advanced node, no Blackwell, no MI400, no custom hyperscaler silicon. The toll bridge analogy gets overused, but ASML is the only gas station for fifty miles on the road to sub-2nm.
Q1 2026 revenue came in at $10.34 billion with diluted EPS of $8.43 and gross margin of 53.0%. CEO Christophe Fouquet said, “The semiconductor industry’s growth outlook continues to solidify, driven by ongoing AI-related infrastructure investments. Demand for chips is outpacing supply. In response, our customers are accelerating their capacity expansion plans for 2026 and beyond.” Management raised full-year 2026 revenue guidance to $42.47B-$47.19B and now sees a 2030 opportunity of $51.91B-$70.78B at 56-60% gross margins.
Backlog tells the story. Q4 2025 backlog stood at $45.06 billion, with quarterly net orders of $15.28 billion, of which $8.60 billion was EUV alone. Shares added 14% last week to $1,863.55, with a YTD gain of 75%. The next name skips the equipment entirely and sells the blueprint.
4. Arm Holdings (ARM): The CPU Standard Is Eating the Data Center The host said Arm Holdings (NASDAQ:ARM) has been looking good, and that is putting it mildly. Arm’s architecture sits inside every smartphone on Earth, and now it is sliding into the data center underneath Google’s Axion, NVIDIA’s Vera, and Microsoft’s Cobalt. When the workload shifted to agentic AI, the CPU stopped being an afterthought.
Q4 FY2026, reported May 6, 2026, showed revenue of $1.49 billion, up 20.1% year over year, with non-GAAP EPS of $0.60. License revenue grew 29% and data center royalty more than doubled. CEO Rene Haas said, “As AI becomes more agentic, demand for Arm AGI CPU, Arm’s first data center chip, has exceeded expectations, reinforcing Arm as the compute platform for the AI era.” Customer demand for the AGI CPU already exceeds $2 billion across FY27-FY28, against a data center CPU TAM Arm pegs at over $100 billion by 2030.
The stock ripped 11% last week to $380.81, with a one-month gain of 72% and a YTD gain of 248%. Friday alone was 11%. The valuation is steep at a 449 P/E, but the design wins are real. The last name on this list is where the AI bookings story reads like a hard backlog.
5. Marvell Technology (MRVL): The Payoff Marvell Technology (NASDAQ:MRVL) is the cleanest pure-play on AI data center interconnect that retail investors can buy. Custom XPU silicon for hyperscalers. 1.6T optics. 51.2T Ethernet switches. The plumbing that decides whether a GPU cluster actually scales or just sits there waiting on bandwidth. I’ve followed the custom-silicon thesis for years, and Marvell’s quarter is the one that finally cracked the case open.
Q1 FY2027, reported May 27, 2026, delivered revenue of $2.417 billion, up 27.6% year over year. Data center revenue hit $1.833 billion, or 76% of the total. CEO Matt Murphy said, “We are seeing exceptional AI-related bookings, and as a result, we are significantly raising Marvell’s revenue outlook for both fiscal 2027 and fiscal 2028.” Q2 guidance points to $2.7 billion at the midpoint, an implied 35% growth rate, with management explicitly telling investors to expect growth to accelerate each quarter throughout fiscal 2027.
The kicker is what happened on Reddit during the breakout. Sentiment on June 8 collapsed to 10 on a wallstreetbets post about “100k+ gain shorting Nebius and Marvell last Thursday”, then flipped to 88 by June 10 as the chopper-loading bulls took over. Shares closed the week up 6% at $279.70, with a YTD gain of 230%. Analyst consensus price target sits at $235.70, which the stock has already blown past, and the rating split is 8 Strong Buy, 31 Buy, 5 Hold.
The Setup The host called the chip sector just spitting distance away from new high territory, and the tape is now there. Five names, five CEOs, one story: AI capex is outrunning supply and the picks-and-shovels providers are guiding sequential acceleration into 2027. KLIC sits at the back end, Lam and ASML own the front end, Arm owns the instruction set, and Marvell owns the interconnect. The breakout already happened. The question is whether you were watching when it did.
SummaryArm Holdings plc is becoming one of the few comprehensive non-GPU AI compounders, supported by accelerating AI CPU adoption across Nvidia, hyperscaler custom silicon programs, and AGI CPU direct sales.Specifically, accelerating traction for custom silicon programs and Nvidia's expanding CPU roadmap is expanding demand for ARM-based architecture, reinforcing ARM's high-margin IP licensing growth opportunity.The AGI CPU is also strategically aligned with the resurgence in server processor demand driven by the agentic AI shift, which is poised to deliver significant earnings accretion for ARM.Taken together, ARM is well positioned for incremental growth and earnings upside beyond management's long-term targets, which remain underappreciated at current levels and support a favorable re-rating backdrop. Sundry Photography/iStock Editorial via Getty Images
Arm Holdings plc (ARM) has been one of the leading semiconductor stocks since the introduction of its first in-house AGI CPU in March. The stock has surged more than 140% since, as markets price in
12.34K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.
Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ahead of their future growth potential. In such a situation, investors find themselves loaded up on expensive shares with limited to no upside or even a downside. So, going all-in on momentum could be risky at times.
A safer approach could be investing in bargain stocks with recent price momentum. While the Zacks Momentum Style Score (part of the Zacks Style Scores system) helps identify great momentum stocks by paying close attention to trends in a stock's price or earnings, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
There are several stocks that currently pass through the screen and Jones Lang LaSalle (JLL - Free Report) is one of them. Here are the key reasons why this stock is a great candidate.
Investors' growing interest in a stock is reflected in its recent price increase. A price change of 4.1% over the past four weeks positions the stock of this financial and professional services company well in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. JLL meets this criterion too, as the stock gained 2.1% over the past 12 weeks.
Moreover, the momentum for JLL is fast paced, as the stock currently has a beta of 1.29. This indicates that the stock moves 29% higher than the market in either direction.
Given this price performance, it is no surprise that JLL has a Momentum Score of B, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped JLL earn a Zacks Rank #2 (Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, JLL is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. JLL is currently trading at 0.52 times its sales. In other words, investors need to pay only 52 cents for each dollar of sales.
So, JLL appears to have plenty of room to run, and that too at a fast pace.
In addition to JLL, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
MNTN’s new HubSpot integration brings Connected TV attribution directly into downstream revenue reporting, enabling Business-to-Business advertisers to tie TV campaigns to measurable revenue.
NEW YORK--(BUSINESS WIRE)--MNTN (NYSE: MNTN), the technology platform bringing performance marketing to Connected TV, today announced a new integration with HubSpot (NYSE:HUBS), the agentic customer platform for scaling businesses. The integration brings Connected TV performance data directly into the CRM workflows B2B marketers use every day and gives brands an unprecedented view into television’s impact across the full customer journey.
The launch positions MNTN as the first CTV platforms to bring TV ad activity directly back into HubSpot, down to the individual contact, so teams can know exactly which prospective customers were exposed to a TV advertisement.
“MNTN was built so that TV can be as measurable and performance-driven as search and social,” said Mark Douglas, President and CEO of MNTN. “As marketers demand more measurable outcomes from television, we believe the next phase of CTV growth will come from tighter integration with the platforms revenue teams already depend on. By making TV more accountable and accessible to Business-to-Business advertisers, we're expanding the universe of brands that can confidently invest in the channel. This integration allows us to connect that missing link of TV performance directly to the pipeline.”
The integration reflects meaningful customer overlap, with more than 90% of MNTN advertisers entering television for the first time. Many are B2B, SaaS, and growth-focused marketers who come to TV with the same expectations they have for search, social, and email: clear attribution, measurable outcomes, and direct visibility into performance.
For these advertisers, the integration closes one of television advertising’s longest-standing visibility gaps by connecting Connected TV directly to the CRM systems they use to measure revenue impact and business growth. Marketers gain:
Full-Funnel Visibility. Attribution data flowing into HubSpot contact records and activity feeds gives advertisers a clear view of how MNTN campaigns drive outcomes, from MQLs and SQLs to pipeline creation. Smarter Sales Outreach. Sales teams can now see whether a prospect was exposed to a MNTN Performance TV campaign, including campaign and creative details, directly within HubSpot contact records, enabling more informed outreach. One Stack, Every Channel. MNTN impressions show directly on a prospect's activity timeline, next to other ad channel activity. “The black box of CTV is no more. With MNTN’s integration into HubSpot, we have a real look at how CTV is directly influencing our efforts across the digital landscape,” said Zach Eberhard, Growth Marketing at Overjet.
The MNTN integration is available now in the HubSpot App Marketplace.
About MNTN
MNTN (NYSE: MNTN) is the Hardest Working Software in Television™, bringing unrivaled performance and simplicity to Connected TV advertising. Our self-serve technology makes running TV ads as easy as search and social and helps brands drive measurable conversions, revenue, site visits, and more. MNTN was named one of Fast Company’s Most Innovative Companies and Next Big Things in Tech and was recently featured on the cover of INC’s Best in Business Issue. For more information, please visit https://mntn.com.
Nice (NICE - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this software company have returned -1.2%, compared to the Zacks S&P 500 composite's +0.5% change. During this period, the Zacks Internet - Software industry, which Nice falls in, has gained 0.2%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Nice is expected to post earnings of $2.63 per share for the current quarter, representing a year-over-year change of -12.6%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.
For the current fiscal year, the consensus earnings estimate of $11.1 points to a change of -9.8% from the prior year. Over the last 30 days, this estimate has remained unchanged.
For the next fiscal year, the consensus earnings estimate of $12.64 indicates a change of +13.9% from what Nice is expected to report a year ago. Over the past month, the estimate has remained unchanged.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Nice is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Nice, the consensus sales estimate for the current quarter of $767.17 million indicates a year-over-year change of +5.6%. For the current and next fiscal years, $3.18 billion and $3.49 billion estimates indicate +7.9% and +9.7% changes, respectively.
Last Reported Results and Surprise HistoryNice reported revenues of $768.62 million in the last reported quarter, representing a year-over-year change of +9.8%. EPS of $2.64 for the same period compares with $2.87 a year ago.
Compared to the Zacks Consensus Estimate of $761.09 million, the reported revenues represent a surprise of +0.99%. The EPS surprise was +4.76%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Nice is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Nice. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Applied Optoelectronics shares are climbing with conviction. What’s behind AAOI gains? What Is Driving Applied Optoelectronics’ Stock Momentum?The latest momentum bid is tied to renewed attention on optical interconnect demand for AI buildouts, with commentary highlighting a path toward "500K+ GPU factories" where copper can become the limiting factor and optics take more of the load. That framing has kept incremental buyers focused on connectivity infrastructure rather than only chip names.
Applied Optoelectronics has also been trading as a Russell 2000 "infrastructure of the AI grid" standout after nearly 900% gains over the past year, keeping momentum traders engaged beyond the mega-cap chip complex.
AAOI Technical Analysis: Key Levels and TrendsAAOI's longer-term trend is still the headline: the stock is up 889.17% over the past 12 months and remains well above its major moving averages, including the 200-day SMA at $73.92 and the 100-day SMA at $118.07. The trend structure also stays constructive with the 20-day SMA above the 50-day SMA (bullish) and a golden cross in August 2025 (50-day SMA above the 200-day SMA).
Near-term, the stock is essentially sitting on its short-term trend gauge, trading just 0.1% above the 20-day SMA ($178.59), which often acts like a "line in the sand" during consolidations. It's also 8.1% above the 50-day SMA ($165.24), so bulls can argue the intermediate trend is intact even if price chops around.
RSI is the cleanest momentum lens right now, and at 49.07 it's neutral—more "reset" than "overheated" after the big run. RSI helps show whether buying or selling has gotten stretched, and this reading suggests neither side has a clear momentum edge at the moment.
From a levels standpoint, the May peak (and 52-week high) at $233.67 is still the big reference point for upside, while the March swing low is the key "trend break" marker on the downside. The stock also saw RSI enter overbought territory in April, which fits the current setup of a high-volatility leader digesting gains rather than trending smoothly.
Key Resistance: $192.00 — a nearby round-number area where rebounds can stall Key Support: $160.00 — a nearby round-number level that sits close to the 50-day EMA ($160.09) Applied Optoelectronics is a provider of fiber-optic networking products across four end markets: internet data center, CATV, telecom and FTTH. It designs and manufactures optical communications products at different levels of integration, components, subassemblies and modules, so it can support customers with anything from parts to more turn-key solutions.
That matters for the current tape because the bull case being traded is about the "connectivity layer" inside AI data centers, where bandwidth and power constraints can push spending toward optical links. The company also has manufacturing and R&D footprints in the U.S., Taiwan and China, which supports its ability to coordinate design, qualification and performance work directly with customers.
AAOI Stock Price MovementAAOI Stock Price Activity: At the time of publication, Applied Optoelectronics shares were up 9.44% at $185.02 on Monday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
An ethanol plant with its giant corn silos next to a cornfield in Windsor, Colorado July 7, 2006./File Photo Purchase Licensing Rights, opens new tab
CompaniesSAO PAULO, June 15 (Reuters) - The International Maritime Organization's decision defining Brazilian corn ethanol's carbon footprint is a landmark step that could position maritime transport as a major future market for the sector, industry executives told Reuters.
In May, the IMO defined the default value of Brazilian corn ethanol's carbon footprint at 20.8 grams of carbon dioxide-equivalent (CO2e) per megajoule, specifically referring to biofuel produced from the country's intermediate or second-corn crop.
The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.
The current average greenhouse gas fuel intensity in shipping is 93.3 grams of CO2e per megajoule, according to the IMO.
The IMO's defined value for Brazilian corn ethanol is a significant step as the agency builds regulations to govern lower-carbon fuels, said Gustavo Mariano, vice president of trading at Inpasa.
"It was a historic and symbolic milestone," Mariano said in an interview, adding that it consolidates the position of Brazilian and South American corn ethanol as a viable fuel for decarbonization.
For decades, Brazil's ethanol industry has been dominated by the country's sugarcane producers. However, according to industry association UNEM, corn ethanol output surged to almost 10 billion liters in the 2025/26 season, up from 2.65 billion liters at the start of the decade.
Once biofuels receive approval for use in shipping, producers could benefit from possible premiums on greener fuels, said Rafael Abud, chief executive of corn ethanol maker FS Fueling Sustainability.
"We have invested heavily in every aspect we can to decarbonize our product," Abud said, citing efforts to lower emissions from biomass use, industrial efficiency and a bioenergy with carbon capture and storage project that could eventually make FS ethanol carbon negative.
The scale of the global shipping industry means Brazil's second-crop corn ethanol will not be in competition with other biofuels such as sugarcane ethanol and biodiesel, but will complement them instead, the executives said.
"If the global bunker market were converted into ethanol equivalent, it would be almost 400 billion liters," Mariano said. "These are volumes so large that we need all sustainable biofuels."
Reporting by Oliver Griffin; Editing by Will Dunham
Our Standards: The Thomson Reuters Trust Principles., opens new tab
After five years with Reuters in Colombia and the Andes, Oliver is now based in Brazil's São Paulo. He covers soft commodities including sugar, coffee, cocoa - among others - as well as some biofuels.
Oxford Industries guided investors toward a $1.50 billion revenue midpoint while undisclosed cost pressures and tariff exposure were already eroding the outlook -- then cut guidance to $1.49 billion, sending OXM down 17%.
NEW YORK--(BUSINESS WIRE)--Shareholders who held Oxford Industries, Inc. (NYSE: OXM) stock lost approximately 17% of their investment value when the company slashed its FY 2026 revenue guidance midpoint to $1.49 billion and projected Q2 sales roughly 5.8% below Wall Street consensus estimates. Those who lost money on OXM are encouraged to submit their information to Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Oxford Industries maintained a FY 2026 revenue guidance midpoint of $1.50 billion through its public communications. The revised FY 2026 guidance lowered revenue guidance midpoint to $1.49 billion and Q2 outlook of approximately $390 million and represented a material reduction from figures investors had relied upon.
Shareholders who suffered losses on their Oxford Industries investment are encouraged to click here to discuss their legal rights with Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
Frequently Asked Questions About the OXM Investigation
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Oxford Industries made materially false or misleading statements regarding its FY 2026 revenue guidance and the underlying cost pressures and tariff exposure that were not reflected in public guidance figures. When the revised outlook was disclosed, the stock price declined 17%.
Q: When did Oxford Industries allegedly mislead investors? A: The investigation focuses on statements made during the period when Oxford Industries maintained its original FY 2026 revenue guidance midpoint of $1.50 billion through public filings and earnings communications, prior to the corrective disclosure that sent the stock lower.
Q: What do OXM investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.
Q: What if I already sold my OXM shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought OXM and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
Q: How long will the investigation take to resolve? A: Securities fraud investigations typically take two to four years from initiation to resolution.
PALO ALTO, Calif.--(BUSINESS WIRE)--Rubrik (NYSE: RBRK), the Security and AI Operations Company, announced that its podcast documentary series, “To Catch a Thief,” has won a prestigious Tribeca X Award during the 25th annual Tribeca Festival in New York City, which recognizes outstanding achievement in story-driven brand collaborations. Produced in partnership with Pod People, “To Catch a Thief” was recognized as the Best Audio/Podcast for its groundbreaking premiere season: “China's Rise to Cyb.
June 15, 2026 08:30 ET | Source: Alto Ingredients, Inc.
PEKIN, Ill., June 15, 2026 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, announced that it has completed a sale transaction with a third-party corporate buyer for all of Alto Ingredients’ 2025 Section 45Z Clean Fuel Production Tax Credits generated from its low-carbon ethanol production.
These credits relate to the company’s 2025 low-carbon transportation fuels produced at both its Pekin Dry Mill and Columbia facilities. The company sold its 2025 tax credits for approximately $8.9 million in cash proceeds, before broker fees and other transaction costs, in line with the company’s previous expectations.
“We are pleased to execute on our strategy to monetize our low-carbon fuel tax credits under Section 45Z,” said Rob Olander, Alto Ingredients’ Chief Financial Officer. “The ability to monetize these credits provides a meaningful source of cash to support our initiatives and increase shareholder value.”
The company expects to continue to benefit significantly from its 2026 and future years’ Section 45Z Clean Fuel Production Tax Credits.
About Alto Ingredients, Inc.
Alto Ingredients, Inc. (NASDAQ: ALTO) is a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients. Leveraging the unique qualities of its facilities, the company serves customers in a wide range of consumer and commercial products in the Health, Home & Beauty; Food & Beverage; Industry & Agriculture; Essential Ingredients; and Renewable Fuels markets. For more information, please visit www.altoingredients.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements and information contained in this communication that refer to or include Alto Ingredients’ estimated or anticipated future results or other non-historical expressions of fact are forward-looking statements that reflect Alto Ingredients’ current perspective of existing trends and information as of the date of the communication. Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,” “plan,” “could,” “should,” “estimate,” “expect,” “forecast,” “outlook,” “guidance,” “intend,” “may,” “might,” “will,” “possible,” “potential,” “predict,” “project,” or other similar words, phrases or expressions. Such forward-looking statements include, but are not limited to, statements concerning Alto Ingredients’ expectation to benefit from and to monetize its 2026 and future years’ Section 45Z Clean Fuel Production Tax Credits. Actual results may differ materially from Alto Ingredients’ current expectations depending upon a number of factors affecting Alto Ingredients’ business and plans. Forward-looking statements are based on current expectations, estimates, assumptions and projections and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, changes in applicable tax laws and regulations or related guidance (including with respect to Section 45Z), Alto Ingredients’ ability to continue to qualify for and generate Section 45Z Clean Fuel Production Tax Credits at anticipated levels, actual operating performance and production volumes, fluctuations in feedstock and energy costs, market conditions and pricing for low-carbon fuels, the availability of and demand from third-party buyers for such tax credits on acceptable terms, and other events, factors and risks previously and from time to time disclosed in Alto Ingredients’ filings with the Securities and Exchange Commission including, specifically, those factors set forth in the “Risk Factors” section contained in Alto Ingredients’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2026.
Company IR and Media Contact:
Michael Kramer, Alto Ingredients, Inc., 916-403-2755 [email protected]
Boston, Massachusetts and Amsterdam, Netherlands, June 15, 2026 (GLOBE NEWSWIRE) -- Food and agriculture has been through a noisy capital cycle. A lot of money chased capital-intensive stories that attempted to rebuild the food system from scratch. Anterra Capital’s view is simpler and more practical. The food system is too large and too entrenched to be replaced, but it can be transformed from within, particularly by companies operating at deep leverage points that can scale on existing industry infrastructure, on economics that make sense from day one.
The close
Fund III's first close, at $100 million against a target of $200 million, marks an important milestone for Anterra. The firm was built on the conviction that the tools that had already transformed other industries — life science tools that reshaped human health, and software that rewired sectors from logistics to financial services — would eventually transition to, and transform, food and agriculture.
“The firm has now successfully navigated two capital cycles in food and agriculture,” said Maarten Goossens, Partner at Anterra Capital. “Each one rewarded the same discipline: backing companies that deliver real returns for their customers and to their investors. What's different this time is that the real-world industries we operate in — large, complex and historically resistant to change — are now ready to be rewired, and the tools to do it have arrived.”
Why Fund III, why now
Food and agriculture remains the largest industry on the planet, roughly $10 trillion in size, employing around 1.3 billion people, nearly 40% of the world's workforce. It is also where a set of structural forces is converging — margin volatility, food security, climate and water constraints, tightening regulation, and health outcomes increasingly tied to what the system produces — each one a reason the old way of operating no longer holds.
Those same forces drew a wave of capital chasing the change they promised. Global investment in food and agriculture technology surged to a historical peak of nearly $52 billion in 2021 before falling back to roughly $16 billion — 2016 levels. Much of that generalist capital backed ambitious, capital-intensive bets that failed to scale: indoor vertical farms, plant-based processed meat alternatives and 10-minute grocery delivery. Anterra took a different approach — backing science-backed companies built on real unit economics and designed to scale through existing industry channels. That retreat of capital from hype back to fundamentals is precisely what now opens the door for disciplined specialists.
And now there is AI — the defining technology shift of our era, and its impact runs deepest in the industries the last generation of software never reached: those which still run on manual workflows, fragmented data and analogue infrastructure. None is larger than food and agriculture. Two engines are now firing at once: vertical AI, the fastest-growing category in enterprise technology with investment tripling in a single year, is finally digitizing how these industries operate; in biology, AI is compressing R&D timelines, shrinking teams and slashing the capital needed to reach a first commercial milestone — unlocking a generation of opportunities that were previously out of reach for venture capital. The capital cycle has cleared the noise. And Anterra has spent twelve years building the knowledge and relationships to deploy into both.
Track record
Anterra's investment thesis has been consistent across two funds — and with valuations reset and AI now changing the economics of building in both software and biology, the moment has finally arrived to deploy it at scale.
Anterra’s first two funds have produced top tier returns and multiple exits, including one of the largest exits ever in early-stage veterinary medicine, a Nasdaq IPO, and several other acquisitions by industry leading strategics across the value chain.
Company-building is a core part of how Anterra operates, deployed where the firm identifies white space the market has not filled. Its first company creation, Enko Chem, is discovering & developing next-generation crop protection chemistry through rational design to replace old, ineffective and unsafe products such as glyphosate, and partnering with key industry leaders, including Syngenta and Bayer Crop Science. Invetx, founded in 2018 and built by the firm from the ground up, applied proven biological approaches from human medicine to veterinary medicine and was acquired by Dechra Pharmaceuticals for over half a billion dollars within 6 years of inception.
Investor base
Anterra's investor base spans institutional investors, food system operators and industry innovators across North America, Europe and APAC. It includes the world's largest food and agriculture bank, one of the largest life sciences investors globally, a leading Asian sovereign wealth fund, and the world's largest animal health company — institutions that understand both the scale of the opportunity and what it takes to capture it. Alongside them sit operators who between them farm more than 13 million acres and include leaders of some of the world's largest CPG, bakery, produce logistics and food retail businesses.
“The vote of confidence from our investor base is what gives this close its weight,” said Adam Anders, Partner at Anterra Capital. “The combination of leading global asset managers, the institutions that know our sector backwards and the operators who farm millions of acres all backing the same thesis is an unrivalled force supporting the Anterra portfolio”.
What’s next
Fund III has already backed Anchr, an AI-native platform modernizing the back office of food distribution — a trillion-dollar industry still running largely on paper — alongside a16z Speedrun. The fund's second investment is Animerra, a veterinary biologics company founded and built by Anterra, applying proven biological approaches to our sector and advancing its science with a lean team at a pace that would not have been possible five years ago.
"We've spent twelve years and two funds proving you can build category-defining companies in food and agriculture — and generate real returns doing it," said Brett Wong, Partner at Anterra Capital. "What's changed is that the world has finally caught up to that thesis. The technology is here, the valuations make sense, and the founders building in this sector are the best we've ever seen. This is the most exciting moment in our firm's history, and Fund III is how we intend to make the most of it."
Media images can be found here.
About Anterra Capital
Anterra Capital is a specialist venture firm investing in food and agriculture, with offices in Amsterdam and Boston. Founded in 2013, the firm manages over $500 million across three funds. Anterra invests in and builds companies that apply life-science and software innovations to food and agriculture. www.anterracapital.com
HAE is a rare genetic disorder that causes recurrent and unpredictable swelling attacks.
The company on Saturday presented the data during a late-breaking session at the European Academy of Allergy & Clinical Immunology Annual Congress 2026, while the results were also published in the New England Journal of Medicine.
Lonvo-Z Meets Key Secondary Endpoints In HAELO StudyThe latest data build on previously announced results showing that the study met its primary endpoint.
During the efficacy evaluation period from weeks five through 28, patients treated with lonvo-z experienced an 87% reduction in mean monthly HAE attacks compared with those receiving placebo.
Researchers also reported that 62% of patients in the lonvo-z group remained both attack-free and therapy-free throughout the six-month evaluation period, compared with 11% of patients in the placebo arm. The difference met a key secondary endpoint with statistical significance.
Safety Profile Remains FavorableAccording to Intellia, lonvo-z demonstrated favorable safety and tolerability across the study.
All treatment-emergent adverse events observed during the primary observation period were classified as mild or moderate. The company reported no serious adverse events among patients receiving lonvo-z.
Analyst Compares To Recently Approved HAE TreatmentsLonvo-z, previously known as NTLA-2002, is designed as a one-time, in vivo CRISPR gene-editing therapy. The treatment aims to permanently reduce kallikrein levels by inactivating the KLKB1 gene following a single dose.
In an investor note on Monday, William Blair wrote, "Additional data on lonvo-z presented at EAACI further substantiated lonvo-z's competitiveness with Q4W donidalorsen on placebo-adjusted HAE attack rate reductions across multiple secondary endpoints."
Analyst Myles Minter further added, "We view these data as furthering
Intellia's case for regulatory approval following its expected completion of a rolling BLA for lonvo-z in the second half of 2026.
NTLA Stock Price Activity: Intellia Therapeutics shares were up 10.57% at $13.39 at the last check on Monday, according to Benzinga Pro data.
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
NEW YORK--(BUSINESS WIRE)--Pagaya Technologies LTD. (NASDAQ: PGY) ("Pagaya" or the “Company”), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced the closing of an upsized $800 million AAA-rated personal loan ABS transaction (PAID 2026-4). With 39 unique investors participating, the upsized deal brings Pagaya's year-to-date personal loan ABS issuance to nearly $4 billion and marks the company's third upsized personal loan ABS transact.
Pagaya Technologies LTD. (NASDAQ: PGY) ("Pagaya" or the “Company”), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced the closing of an upsized $800 million AAA-rated personal loan ABS transaction (PAID 2026-4).
With 39 unique investors participating, the upsized deal brings Pagaya’s year-to-date personal loan ABS issuance to nearly $4 billion and marks the company’s third upsized personal loan ABS transaction this calendar year. The deal brings Pagaya’s total issuance since 2018 to $40 billion through 91 ABS transactions, backed by more than 165 institutional investors across its personal loan, auto and POS programs. Notably, collateral for this transaction includes personal loans from new network partners including Upstart and Achieve.
“The upsizing of our last two PAID transactions highlights the strength of our funding platform and the confidence institutional investors continue to place in Pagaya’s underwriting and asset performance,” said Sahil Chandiramani, Head of Capital Markets at Pagaya. “This transaction further expands our capacity to support both existing and new lending partners as they grow, while continuing to deliver attractive investment opportunities to the market.”
About Pagaya Technologies
Pagaya (NASDAQ: PGY) is a global technology company making life-changing financial products and services available to more people nationwide, as it reshapes the financial services ecosystem. By using machine learning, a vast data network and an AI-driven approach, Pagaya provides consumer credit and other products for its partners, their customers, and investors. Its proprietary API and capital solutions integrate into its network of partners to deliver seamless user experiences and greater access to the mainstream economy. For more information, visit pagaya.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260615808339/en/
On June 15, 2026, we delve into the DCF analysis for The Toronto-Dominion Bank TD , which has shown impressive price performance over the past year. The stock has appreciated significantly, with a year-to-date increase of 26.6% and a remarkable 71.9% rise over the past year. Here are some key points to consider:
DCF Earnings-based intrinsic value of $83.11 compared to the current price of $117.33, indicating a margin of safety of -30.3%. DCF FCF-based intrinsic value stands at $-53.59, suggesting a second opinion on valuation. GF Score™ of 74/100 indicates a moderate reliability of the DCF inputs. What Is TD Worth? DCF Earnings-Based Model The DCF earnings-based model for TD utilizes a two-stage approach to estimate its intrinsic value. The first stage considers a growth phase where earnings per share (EPS) is projected to grow at a rate of 6.2% annually for the next ten years. The second stage accounts for a terminal growth rate of 4% for the subsequent ten years. The discount rate applied is 11%, which combines the risk-free rate and the equity risk premium.
Parameter Value Current EPS (TTM, excl. non-recurring) $6.66 10-Year Growth Rate 6.2% 10-Year Treasury Rate 4.45% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% The calculation summary for the two-stage model is as follows:
Stage Description Value Growth Stage (Years 1-10) EPS growing at 6.2%, discounted at 11% $52.66 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $30.45 Intrinsic Value Growth + Terminal $83.11 With the current price at $117.33, the intrinsic value of $83.11 indicates that TD is modestly overvalued, with a margin of safety of -30.3%. It is important to note that GuruFocus utilizes EPS excluding non-recurring items, as research indicates that stock prices correlate more closely with earnings than free cash flow. For further calculations, you can visit the TD DCF Calculator.
What Does the Free Cash Flow DCF Say? The free cash flow (FCF) based DCF model presents a stark contrast to the earnings-based model, yielding an intrinsic value of $-53.59. This significant discrepancy highlights the potential disagreement between the two valuation methods. The FCF-based model suggests that TD is significantly overvalued, with a margin of safety of -100.0%.
How Does GF Value™ Compare to the DCF Models? The GF Value™ of $80.05 provides a third perspective on TD's valuation. This proprietary measure is calculated based on historical trading multiples, past business growth, and future performance estimates. The GF Value™ aligns with the earnings-based DCF model, indicating that all three models suggest TD is overvalued.
For more insights, you can check the GF Value™ page.
What Does TD's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have historically generated higher long-term returns (backtested from 2006 to 2021).
Metric Rating GF Score™ 74/100 Financial Strength 2/10 Profitability 6/10 Growth 9/10 Valuation 3/10 Momentum 9/10 With a predictability rank of 3/5 stars, this indicates that the DCF model is moderately reliable for TD. For more details, visit the TD stock page.
Key Assumptions and Limitations It is essential to recognize that DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Additionally, stocks with low predictability ratings tend to produce less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not reflect future market conditions accurately.
What This Means for Investors In summary, the three valuation models—DCF earnings, DCF FCF, and GF Value™—converge on the conclusion that TD is overvalued at its current price of $117.33. The earnings-based intrinsic value of $83.11 and the FCF-based intrinsic value of $-53.59, along with the GF Value™ of $80.05, all suggest caution for potential investors.
For the full DCF analysis, visit the TD DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.
Frequently Asked Questions What is TD's intrinsic value based on DCF?
Answer: earnings-based $90.07, FCF-based $-53.59
Is TD overvalued or undervalued?
Answer: Based on the DCF and GF Value™ consensus, TD is overvalued.
How reliable is the DCF model for TD?
Answer: The predictability rank of 3/5 indicates a moderate reliability of the DCF model for TD.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
UFC Freedom 250 made history on June 14 as the only Ultimate Fighting Championship event to end all fights by knockout, but UFC stock had also suffered a rather heavy blow prior to the spectacle and is yet to recover from it.
Namely, the shares of UFC parent company TKO Group Holdings (NYSE: TKO) dropped nearly 5% on Friday, June 12, erasing a huge chunk of the weekly gains as investors shifted their focus to the White House UFC match.
The White House South Lawn fight itself, which reportedly cost $60 million to organize, did very little to reverse last Friday’s losses, as the stock is up only 1.3% in pre-market trading at the time of writing, Monday, June 15, when it sat at $206.
TKO stock price June 15. Source: Google Finance Still, investors were quick to note the uptick, some attributing it to the fact that CEO Dana White was a top donor during Donald Trump’s presidential campaign, whose birthday UFC 250 was commemorating.
While the fight has certainly boosted visibility for the brand due to its connections with the Trump family, another, more practical catalyst emerged on Monday in the form of institutional moves involving TKO shares.
Specifically, NFJ Investment Group disclosed the purchase of 18,990 shares valued at roughly $3.97 million in the fourth quarter, according to the firm’s latest SEC filing. It’s worth noting, however, that the disclosures are based on Form 13F data, which reflects positions at quarter-end and can lag by up to 45 days.
Moreover, a significant portion of market attention is also being directed to TKO’s upcoming dividend deadline. Indeed, shareholders must be on record by the close of today’s session to qualify for the payout on June 30, when Class A shareholders are set to receive $0.79 per share. As for future payments, the company has indicated they would be reviewed quarterly based on earnings, leverage, cash flow, and broader market conditions.
Featured image via Shutterstock
Best Crypto Exchange for Intermediate Traders and Investors
Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.
0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
Copy top-performing traders in real time, automatically.
eToro USA is registered with FINRA for securities trading.
30+ million Users worldwide
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.
Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!
Markham, Ontario--(Newsfile Corp. - June 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of June 2026, which is payable on July 15, 2026 to shareholders of record at the close of business on June 30, 2026. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada).
About Extendicare
Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Network brands. We are committed to delivering quality care to meet the needs of the growing seniors' population, inspired by our mission to provide people with the care they need, wherever they call home. We operate a network of 99 long-term care homes (59 owned, 40 under management contracts), deliver approximately 24.5 million hours of home health care services annually, and provide group purchasing services to third parties representing approximately 157,100 beds across Canada. Extendicare proudly employs approximately 31,500 individuals and manages an additional 5,000 joint venture employees, all of whom are highly qualified, trained and dedicated team members and passionate about providing high-quality care and services to help people live better.
Forward-looking Statements
Information provided by Extendicare from time to time, including this release, contains or may contain forward-looking statements concerning anticipated future events, results, circumstances, economic performance or expectations with respect to Extendicare and its subsidiaries, including, without limitation: statements regarding its dividend levels, business operations, business strategy, growth strategy, results of operations and financial condition. Forward-looking statements can often be identified by the expressions "anticipate", "believe", "estimate", "expect", "intend", "objective", "plan", "project", "will", "may", "should" or other similar expressions or the negative thereof. These forward-looking statements reflect the Company's current expectations regarding future results, performance or achievements and are based upon information currently available to the Company and on assumptions that the Company believes are reasonable. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied in the statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on Extendicare's forward-looking statements. Further information can be found in the disclosure documents filed by Extendicare with the securities regulatory authorities, available at www.sedarplus.ca and on Extendicare's website at www.extendicare.com. Except as required by applicable securities laws, the Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301480
Source: Extendicare Inc.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
SCHAFFHAUSEN, Switzerland--(BUSINESS WIRE)--Aptiv PLC (NYSE: APTV), a global industrial technology leader, will showcase advanced solutions at Automate 2026 for powering robotics and automation applications, which are engineered to be smarter, safer and more cost-effective. Building on decades of innovation, these offerings draw on Aptiv's differentiated portfolio to enable devices and systems to sense, think, act, and be continuously optimized to support the next wave of intelligent systems. “.
eToro could become the latest in a string of FinTechs entering the banking space.
The trading and investment platform is considering multiple acquisitions, and also planning an expansion into traditional payment services that could involve a banking license application, CEO Yoni Assia said in an interview with the Financial Times (FT) Monday (June 20).
The company is working with investment bankers to purchase two businesses “soon,” Assia said, adding that the firms in question were wealth-technology businesses, one in the U.S. and another based outside the U.S.
“We are very acquisitive — it is part of the reason why we listed,” the CEO said. “We have a number of potential deals we are looking at including businesses who would help us grow our wealth offering. We remain committed to growing our global footprint including expanding the U.S. market.”
This follows eToro’s acquisition of crypto company Zengo in April, a $70 million deal designed to strengthen the company’s ability to offer things like tokenized assets and rising decentralized trading models like prediction markets and perpetuals.
“We believe the future of finance will be increasingly digital, decentralized and user-controlled, with self-custody playing an important role in that evolution,” Assia said at the time.
Advertisement: Scroll to Continue
He told the FT he expects further deals in the FinTech space as that sector deals with a funding strain brought on by higher interest rates.
“The key is for diversification into more payments services … and that could see us consider applying for banking licences in the future, or buying a bank,” Assia said, adding that the company would focus more on payments than lending.
As the FT notes, the past several months have seen a wave of FinTechs apply for banking licenses, after the Trump administration relaxed regulations for becoming chartered lenders.
In 2025, the Office of the Comptroller of the Currency received 14 applications de novo charters, many of them from FinTechs. That number nearly equaled the total applications the regulator received in the prior four years combined.
This year has already seen the Latin American financial services giant Nu get conditional approval to establish a U.S. bank. U.K.-based digital lender Revolut also plans to launch an American banking operation.
“A predominant feature of the current charter wave is that many applicants are not seeking to become traditional banks,” PYMNTS wrote earlier this year. “Instead, they are pursuing licenses that allow them to perform specific financial functions.”
OneSpan helps organizations unlock the value of digital credentials for customer onboarding and authentication
LAS VEGAS & BOSTON--(BUSINESS WIRE)--OneSpan Inc. (NASDAQ: OSPN) will showcase its latest innovations in digital identity and authentication at Identiverse 2026, June 15–17 in Las Vegas (Booth #827), including an early-access release of its digital credentials solution, designed to simplify the way organizations issue, manage, and verify identities across digital wallets.
As digital identity wallets rapidly gain traction, fueled by regulatory momentum such as eIDAS 2.0 and rising demand for more secure, user-friendly identity experiences, organizations are under increasing pressure to modernize their user onboarding and authentication processes. The timeline is accelerating: EU member states must make digital identity wallets available by December 2026, and by December 2027, banks and other relying parties must support them for user onboarding and authentication.
At Identiverse, OneSpan will demonstrate how organizations can move beyond fragmented approaches and adopt digital credentials in a scalable, practical way without the complexity of integrating multiple wallets, standards, and trust frameworks.
"Digital credentials represent a fundamental shift in how identity is established and reused across digital interactions," said Ashish Jain, Chief Technology Officer at OneSpan. "Organizations need a practical way to adopt these technologies without navigating the complexity of multiple wallets, standards, and trust frameworks. OneSpan is helping customers bridge today's authentication infrastructure with tomorrow's credential-based identity ecosystem."
Digital credentials enable a trusted, reusable identity that can be securely shared across services, reducing reliance on traditional verification methods such as document uploads and selfies, which continue to introduce friction and growing exposure to fraud, including AI-driven attacks. By simplifying how organizations connect to a fragmented digital wallet ecosystem, OneSpan enables the secure issuance and verification of digital credentials across multiple wallets through a single integration layer, making adoption more practical, scalable, and ready for real-world deployment.
Digital credentials are becoming a foundational component of the future identity ecosystem, where trust is portable and reusable across digital interactions. Realizing this future depends on making adoption practical today. By combining digital credentials with existing authentication methods, MFA, and passkeys, OneSpan enables organizations to introduce credential-based experiences without disrupting current user journeys while building toward a credential-first future.
Attendees visiting Booth #827 will see live demonstrations of how digital credentials can be seamlessly integrated into onboarding, authentication, and other high-value customer journeys, unlocking new efficiencies and business opportunities.
As part of this showcase, OneSpan is inviting organizations to sign up for early access to its upcoming digital credentials solution. Participants will gain early insight into how to prepare for the shift to wallet-based identity ahead of general availability in the coming weeks.
About OneSpan
OneSpan helps organizations build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity and Digital Agreements. Our cybersecurity solutions protect identities, secure mobile apps, and safeguard access through advanced high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks. Our digital agreements solutions streamline agreement workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance, and exceptional customer experiences. Trusted by leading global enterprises, including more than 60% of the world’s 100 largest banks, OneSpan processes over 100 million digital agreements and billions of secure authentication transactions across more than 120 countries each year.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable U.S. securities laws, including statements regarding the expected capabilities, availability, and benefits of OneSpan’s digital credentials solution, the anticipated timing of its general availability, and the expected evolution and adoption of digital credentials and identity technologies. Forward-looking statements may be identified by words or phrases such as "seek", "believe", "plan", "estimate", "anticipate", “expect", "intend", "continue", "outlook", "may", "will", "should", "could", or "might" and other similar expressions. These forward-looking statements involve risks and uncertainties, as well as assumptions that, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Factors that could materially affect our business and financial results include, but are not limited to the factors described in the “Risk Factors” section of our Annual Report on Form 10-K, as updated by the “Risk Factors” section of our Quarterly Reports on Form 10-Q. Our filings with the Securities and Exchange Commission (the “SEC”) and other important information can be found in the Investor Relations section of our website at investors.onespan.com. We do not have any intent, and disclaim any obligation, to update the forward-looking information to reflect events that occur, circumstances that exist or changes in our expectations after the date of this press release, except as required by law.
Unless otherwise noted, references in this press release to “OneSpan”, “Company”, “we”, “our”, and “us” refer to OneSpan Inc. and its subsidiaries.
For more information, go to www.onespan.com. You can also follow @OneSpan on X or visit us on LinkedIn and Facebook.
Bitmine owns 4.66% of the total ETH coin supply of 120.7 million
Bitmine is 93% of the way to the 'Alchemy of 5%' in just 11 months
Bitmine named to Fortune Crypto 100 list for 2026, a definitive ranking of the most influential companies in blockchain
Bitmine closed on its sale of 3,500,000 shares of 9.50% Series A Perpetual Preferred Stock on June 10, 2026
Bitmine's Series A Preferred Stock will trade on the NYSE under the symbol BMNP beginning on June 16, 2026
Ethereum continues to benefit from the dual tailwinds of Wall Street tokenizing on the blockchain and from agentic AI systems increasingly needing public and neutral blockchains
Bitmine has 4,718,677 staked ETH, representing $8.1 billion at $1,718 per ETH
MAVAN (Made in America VAlidator Network) is a premier Ethereum staking destination for BMNR and institutional investors, with a focus on security, performance, and resilience
Bitmine owns $88 million of Eightco (NASDAQ: ORBS), now one of the only publicly listed equities in the world to provide investors indirect exposure to OpenAI
Bitmine Crypto + Total Cash Holdings & Marketable Securities + "Moonshots" total $10.4 billion, including 5.62 million ETH tokens, total cash & marketable securities of $502 million, and other crypto holdings
Bitmine leads crypto treasury peers by both the velocity of raising crypto NAV per share and by the high trading liquidity of BMNR stock
Bitmine is the 203rd most traded stock in the US, trading $550 million per day (5-day avg)
Bitmine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support Bitmine's goal of acquiring 5% of ETH
, /PRNewswire/ -- (NYSE: BMNR) Bitmine Immersion Technologies, Inc. ("Bitmine" or the "Company") a Bitcoin and Ethereum Network company with a focus on the accumulation of crypto for long term investment, today announced Bitmine crypto + total cash & marketable securities + "moonshots" holdings totaling $10.4 billion.
BITMINE Weekly Update
STAKING: BMNR now staking over 4.7 million ETH
ALCHEMY of 5%: BMNR ranked #203 by 5D avg $ volume
As of June 14, 2026 at 6:00pm ET, the Company's crypto holdings are comprised of 5,620,754 ETH at $1,718 per ETH (per CoinbaseNASDAQ: COIN), 204 Bitcoin (BTC), $180 million stake in Beast Industries, $88 million stake in Eightco Holdings (NASDAQ: ORBS) ("moonshots") and total cash & marketable securities of $502 million. Bitmine's ETH holdings are 4.66% of the ETH supply (of 120.7 million ETH).
On June 10, Bitmine closed its offering (the "offering") registered under the Securities Act of 1933, as amended (the "Securities Act"), of 3,500,000 shares of 9.50% Series A Perpetual Preferred Stock (the "Series A Preferred Stock"), at a public offering price of $80.00 per share. The Company received net proceeds from the offering of approximately $273.8 million, after deducting the underwriting discounts and commissions and the Company's estimated offering expenses. The Series A Preferred Stock is expected to begin trading on the NYSE under the symbol BMNP beginning June 16, 2026. The dividends for BMNP are scheduled to be paid weekly, subject to the terms of the applicable Certificate of Designations.
"The Series A Preferred Stock offering is good balance sheet diversification for Bitmine. The Company's current projected annualized staking rewards of approximately $219 million provide recurring cash flow to support the dividends related to the Series A Preferred shares," stated Thomas "Tom" Lee, Chairman of Bitmine.
On June 11, 2026, Bitmine was named to the Fortune 100 Crypto List (link here). Fortune published this definitive ranking of the most influential companies in blockchain and draws on rigorous data analysis by Inca Digital and a survey of leading crypto experts, according Fortune Magazine.
On May 11, 2026, Bitmine released the latest Chairman's Message (link here) for May 2026.
"Over the past week, we acquired 76,881 ETH. We are maintaining a somewhat elevated pace of buying as we believe this pullback in ETH prices does not reflect the strengthening of Ethereum fundamentals. This is not surprising given we believe we are in the early stages of crypto spring. Bitmine is expected to reach the 'alchemy of 5%' sometime in 2026," stated Mr. Lee.
Bitmine recently launched MAVAN (the Made in American VAlidator Network), the institutional grade staking platform. While MAVAN was originally developed to support Bitmine's own Ethereum treasury, MAVAN intends to expand to serve institutional investors, custodians, and ecosystem partners seeking best-in-class staking infrastructure. A portion of Bitmine's ETH is already staked on the MAVAN platform.
As of June 14, 2026, Bitmine total staked ETH stands at 4,718,677 ($8.1 billion at $1,718 per ETH). "Bitmine has staked more ETH than other entities in the world. At scale (when Bitmine's ETH is fully staked by MAVAN and its staking partners), the projected ETH staking reward is $269 million on an annualized basis (using 2.79% 7-day BMNR yield)," stated Lee.
"Annualized staking revenues are now projected at $226 million. And this 4.7 million ETH is over 83% of the 5.62 million ETH held by Bitmine. Bitmine's own staking operations generated a 7-day yield of 2.79% (annualized)," continued Lee.
Bitmine's crypto holdings reign as the #1 Ethereum treasury and #2 global treasury, behind Strategy Inc. (NASDAQ: MSTR), which reportedly owns 845,256 BTC valued at $54 billion. Bitmine remains the largest ETH treasury in the world.
Bitmine is one of the most widely traded stocks in the US. According to data from Fundstrat, the stock has traded average daily dollar volume of $550 million (5-day average, as of June 12 2026), ranking #203 in the US, behind Oklo Technologies (rank #202) and ahead of Parker-Hannifin (rank #204) among 5,704 US-listed stocks (statista.com and Fundstrat research).
Bitmine management believes the GENIUS Act and Securities and Exchange Commission's (the "SEC") Project Crypto are as transformational to financial services in 2025 as US action on August 15, 1971 ending Bretton Woods and the USD on the gold standard 54 years ago. This 1971 event was the catalyst for the modernization of Wall Street, creating the iconic Wall Street titans and financial and payment rails of today. These proved to be better investments than gold.
The Company also announced that the Board of Directors has declared the third weekly cash dividend in the amount of $0.2639 per share on the outstanding shares of the Company's Series A Preferred Stock, which is expected be paid on July 6, 2026 to holders of record of the Series A Preferred Stock as of the close of business on June 26, 2026.
The Chairman's message can be found here:
https://www.Bitminetech.io/chairmans-message
The Fiscal Full Year 2025 Earnings presentation and corporate presentation can be found here: https://Bitminetech.io/investor-relations/
To stay informed, please sign up at: https://Bitminetech.io/contact-us/
About Bitmine
Bitmine (NYSE: BMNR) is a Bitcoin miner with operations in the US. The company is deploying its excess capital to be the leading Ethereum Treasury company in the world, implementing an innovative digital asset strategy for institutional investors and public market participants. Guided by its philosophy of "the alchemy of 5%," the Company is committed to ETH as its primary treasury reserve asset, leveraging native protocol-level activities including staking and decentralized finance mechanisms. The Company launched MAVAN (Made-in America VAlidator Network), a dedicated staking infrastructure for Bitmine assets, in 2026.
For additional details, follow on X:
https://x.com/bitmnr
https://x.com/fundstrat
Forward Looking Statements
This press release contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. These forward-looking statements can be identified by terms such as "expects," "projects," "projected," "intends," "believes," "anticipates," "estimates," and similar expressions. This document specifically contains forward-looking statements regarding: (i) the Company's goals regarding ETH acquisition, including the 'Alchemy of 5%' initiative and the expectation that Bitmine will reach this goal sometime in 2026; (ii) the Company's beliefs and expectations regarding the cryptocurrency market, including that Ethereum continues to benefit from the dual tailwinds of Wall Street tokenizing on the blockchain and agentic AI systems increasingly needing public and neutral blockchains; (iii) the expected trading of the Series A Preferred Stock on the NYSE under the symbol BMNP beginning June 16, 2026; (iv) the dividend payment schedule for the Series A Preferred Stock, including the expectation that the third weekly cash dividend will be paid on July 6, 2026 to holders of record as of June 26, 2026; (v) the Company's digital asset accumulation strategy and staking operations, including projected annualized ETH staking rewards of approximately $269 million (when Bitmine's ETH is fully staked by MAVAN and its staking partners) and current projected annualized staking revenues of approximately $226 million; (vi) MAVAN's intended expansion to serve institutional investors, custodians, and ecosystem partners seeking best-in-class staking infrastructure; (vii) the Company's characterization of current market conditions as the "early stages of crypto spring" and the belief that ETH price pullbacks do not reflect the strengthening of Ethereum fundamentals; (viii) management's belief that the GENIUS Act and SEC Project Crypto are as transformational to financial services as US action on August 15, 1971 ending Bretton Woods and the USD gold standard; and (ix) continued growth and advancement of the Company's Ethereum treasury strategy. In evaluating these forward-looking statements, you should consider various factors, including: Bitmine's ability to keep pace with new technology and changing market needs; Bitmine's ability to finance its current business, Ethereum treasury operations, and proposed future business; the competitive environment of Bitmine's business; market conditions affecting the trading price of the Company's common stock and Series A Preferred Stock; regulatory developments affecting digital assets, including the ultimate enactment and implementation of pending legislation and SEC initiatives; the volatility and unpredictability of digital asset prices; the performance, reliability, and security of the Company's staking operations; risks related to AI systems and their impact on cryptocurrency markets; and the future value of Bitcoin and Ethereum. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond Bitmine's control, including those set forth in the Risk Factors section of Bitmine's Form 10-K filed with the SEC on November 21, 2025, as well as all other SEC filings, as amended or updated from time to time. Copies of Bitmine's filings with the SEC are available on the SEC's website at www.sec.gov. Bitmine undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Appoints Fiserv Executive Takis Georgakopoulos as Chief Executive Officer Bringing Payments, Technology, and Financial Services Experience to the Role
Mike Lyons Steps Down to Become CEO of Truist Financial Corporation
MILWAUKEE, June 15, 2026 (GLOBE NEWSWIRE) -- Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology solutions, today announced that Takis Georgakopoulos has been appointed Chief Executive Officer (CEO) and as a member of the Board of Directors, effective immediately. He succeeds Mike Lyons, who has stepped down as CEO and member of the Board of Directors to return to banking and become CEO of Truist Financial Corporation.
Mr. Georgakopoulos joined Fiserv in late 2024 and brings more than two decades of payments, technology, financial services, AI, and cybersecurity experience to the role. As a member of the Fiserv executive team, he has been leading and partnering across the company’s Financial Solutions and Merchant Solutions businesses to capitalize on the opportunities in these converging markets. Mr. Georgakopoulos will continue to focus on delivering best-in-class technology across the enterprise and remain closely engaged with the Merchant Solutions business to drive positive client outcomes.
Most recently, Mr. Georgakopoulos served as Fiserv’s Co-President leading Technology and Merchant Solutions and previously as Chief Operating Officer, Technology and Merchant Solutions. Prior to his tenure at Fiserv, he served as Global Head of Payments for J.P. Morgan’s Corporate and Investment Bank, where he oversaw all aspects of the business including technology, product, sales, and operations. Earlier in his career, he was a partner at McKinsey & Company, advising large financial institutions.
Gordon Nixon, Chairman of the Fiserv Board of Directors, said, “Takis is an exceptional leader whose strategic vision, technical depth, and knowledge of our clients have been instrumental since he joined Fiserv. During this time, he has driven meaningful progress in modernizing our merchant platform, accelerating Clover, and embedding AI across our infrastructure. He is the right leader to guide Fiserv in an industry being reshaped by rapid advances in technology, innovation, AI, and cybersecurity.”
Nixon added, “The Board has great confidence in the company's strategy outlined at Investor Day and in Takis's ability to lead Fiserv, execute the One Fiserv action plan, and optimize shareholder value for the long-term.”
Mr. Georgakopoulos commented, “I am honored to serve as CEO of Fiserv. The company has leading positions across finance and commerce, a unique ability to enable financial transactions across financial institutions, merchants, and consumers, the scale to compete and win, and the most talented team in the industry. I look forward to working closely with the Board and leadership team as we continue to advance the strategic priorities we laid out at Investor Day.”
Mr. Nixon added, “We appreciate Mike's leadership during an important period for the company. On behalf of the Board, we wish him all the best in his new role.”
Mr. Lyons said, “I’m proud of what the team has accomplished over the past year. I have great confidence in the Company's strong platform, talented leadership team, and dedicated associates and look forward to partnering with Fiserv as a client in the years ahead.”
Reaffirming 2026 Outlook
The company is reaffirming its outlook for the full year 2026 as provided on May 5, 2026. Fiserv continues to expect organic revenue growth of 1% to 3% and adjusted earnings per share of $8.00 to $8.30 for 2026.
Additional information regarding our current outlook, including the definitions of the non-GAAP financial measures referenced herein and related reconciliations, is included in our earnings release dated May 5, 2026, which is available on our investor relations website.
About Takis Georgakopoulos
Takis Georgakopoulos joined Fiserv in 2024 as an Executive Vice President and member of the Management Committee and became Chief Operating Officer, Technology and Merchant Solutions in April 2025 and Co-President and Head of Merchant Solutions and Technology in December 2025. Before joining Fiserv, he served as Global Head of Payments for J.P. Morgan’s Corporate & Investment Bank, where he oversaw all aspects of the business, including technology, product, sales, and operations.
About Fiserv
Fiserv, Inc. (NASDAQ: FISV), a Fortune 500 company, is a global leader uniting commerce and finance. The company powers sustained growth and innovation at scale for financial institutions and businesses worldwide across payments, account processing, digital banking, merchant acquiring, network services, e-commerce, and Clover®, the all-in-one business management platform. Fiserv is a member of the S&P 500® Index and one of FORTUNE® America’s Most Innovative Companies. Visit fiserv.com and follow on social media for more information and the latest company news.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding anticipated organic revenue growth, adjusted earnings per share and other statements regarding our future financial performance. Statements can generally be identified as forward-looking because they include words such as “believes,” “anticipates,” “expects,” “could,” “should,” “confident,” “likely,” “plan,” or words of similar meaning. Statements that describe the company’s future plans, outlook, objectives or goals are also forward-looking statements.
Forward-looking statements are subject to assumptions, risks and uncertainties that may cause actual results to differ materially from those contemplated by such forward-looking statements. The factors that could cause the company’s actual results to differ materially include, among others, the following: the company’s ability to compete effectively against new and existing competitors and to continue to introduce competitive new products and services on a timely, cost-effective basis; changes in customer demand for the company’s products and services; the ability of the company’s technology to keep pace with a rapidly evolving marketplace; the company’s ability to successfully implement and achieve the expected benefits associated with its One Fiserv action plan; the success of the company’s merchant alliances, some of which are not controlled by the company; the impact of a security breach or operational failure on the company’s business, including disruptions caused by other participants in the global financial system; losses due to chargebacks, refunds or returns as a result of fraud or the failure of the company’s vendors and merchants to satisfy their obligations; changes in local, regional, national and international economic or political conditions, including those resulting from heightened inflation, rising interest rates, taxes, trade policies and tariffs, a recession, bank failures, or international hostilities, and the impact they may have on the company and its employees, clients, vendors, supply chain, operations and sales; the company’s ability to use artificial intelligence to improve its products and services and enhance its operations; the effect of proposed and enacted legislative and regulatory actions affecting the company or the financial services industry as a whole; the company’s ability to comply with government regulations and applicable card association and network rules; the protection and validity of intellectual property rights; the outcome of pending and future litigation and governmental proceedings; the company’s ability to successfully identify, complete and integrate acquisitions, and to realize the anticipated benefits associated with the same; the impact of the company’s growth strategies; the company’s ability to attract and retain key personnel; adverse impacts from currency exchange rates or currency controls; changes in corporate tax and interest rates; and other factors included in “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in other documents that the company files with the Securities and Exchange Commission, which are available at http://www.sec.gov. You should consider these factors carefully in evaluating forward-looking statements and are cautioned not to place undue reliance on such statements. The company assumes no obligation to update any forward-looking statements, which speak only as of the date of this news release.
Media Relations:
Stacy Davidson
Chief Communications and Marketing Officer
Fiserv, Inc. [email protected]
Investor Relations:
Walter Pritchard
Senior Vice President, Investor Relations
Fiserv, Inc. [email protected]
HomeIndustriesBankingThe financial-services company ‘continues to look strategically adrift,’ an analyst says, as the stock falls furtherPublished: June 15, 2026 at 9:36 a.m. ET
In just over 13 months as the CEO of Fiserv, Mike Lyons presided over a 71% stock drop. Now shares of the financial-technology company are falling further toward a 10-year low after news of Lyons’ unexpected departure for a new role.
The company, which sells payment-processing, mobile-banking and other services to both merchants and financial clients, announced Monday morning that Lyons is departing to become CEO of Truist Financial. Succeeding him, effective immediately, is Takis Georgakopoulos, who’s been with the company since late 2024 and most recently served as a co-president focused on technology and merchant solutions.
SanDisk (NASDAQ: SNDK) stock’s remarkable 5,302% rally since it got spun off from Western Digital (NASDAQ: WDC) in 2025 came at the cost of SNDK flashing a strong sell signal after becoming one of the most overbought equities in history.
Specifically, by the time the markets closed on Friday, June 12, the memory firm saw its relative strength index (RSI) cross above 99 on a scale that tops at 100.
SanDisk stock price and RSI chart. Source: Barchart While such a reading would traditionally be a strong sell signal, SanDisk’s relatively brief time as a separate public company in its current iteration and the narrative-driven nature of the wider ongoing rally make determining if SNDK is bound for a correction difficult to gauge.
Why SanDisk stock might not be a ‘Sell’ despite record high RSI Indeed, the company owes much of its success to the ongoing artificial intelligence (AI) boom, and the backing it received from Jensen Huang’s remarks that memory represents the next major technological bottleneck, and from the buying activity of the increasingly popular Leopold Aschenbrenner.
Should the prevailing Wall Street narrative remain relevant in the coming years, there is little reason for SanDisk stock to halt its overall uptrend, even if it suffers temporary corrections.
Indeed, the various notes issued in recent months regarding the sector almost universally foresee the hardware shortages – and elevated prices – to remain a factor at least until 2028.
Similarly, Nvidia’s (NASDAQ: NVDA) CEO opined that memory will remain a significant factor for years to come, effectively forecasting firms like SanDisk can expect to benefit from market undersupply and high demand long-term.
Elsewhere, the historical patterns from a different company in an adjacent industry – Micron (NASDAQ: MU) – indicate that an SNDK stock correction is not imminent.
Specifically, MU shares have historically enjoyed up to a year of continued soaring even after their RSI hit overbought levels, indicating a possibility that the technical sell signal does not guarantee an immediate sell-off.
SanDisk stock performance in June 2026 Looking at SanDisk stock’s short-term performance, it would appear that investors have not taken the sky-high RSI as a warning signal by press time on June 15.
After SNDK shares rallied 619.41% year-to-date (YTD), they extended their last-session 5.24% gains by rising another 5.93% with a rise from $1,980.10 at the latest closing bell to $2,097.57 in the Monday pre-market.
SanDisk stock price all-time chart with 2026 performance highlighted. Source: Google Still, it is worth noting that the situation in the extended session is peculiar on account of the Sunday memorandum of understanding (MOU) – sometimes reported as a peace deal – between Iran and the U.S., providing powerful external headwinds across most sectors.
How a massive SanDisk stock sell-off could start Lastly, SanDisk stock could soon turn into a sell regardless of technical analysis (TA) signals. June brought a heated discussion over the costs of AI as some retail users were also moved to usage-based billing.
The debate has led to a trend of companies – including central firms such as Meta Platforms (NASDAQ: META) – scaling down their usage of the technology.
Considering the scale of investments in the sector and the degrees of debt various major firms have taken on to fund their AI program, a shift could prove devastating for company revenues and valuations across big tech.
With its exceedingly high RSI and the scale of its overall rally, SNDK stock could prove especially vulnerable to a sell-off.
Memory and storage stocks are surging on the morning of Monday, June 15, after news of a U.S.-Iran peace agreement reopened risk appetite across global equities. Micron Technology (NASDAQ:MU | MU Price Prediction) stock is up 8% to around $1,060 in early action, climbing back above the $1,000 level.
Western Digital (NASDAQ:WDC) stock is up 8% to $607, while SanDisk (NASDAQ:SNDK) shares are trading higher by 6% to around $2,101. The Roundhill Memory ETF (CBOE:DRAM) advanced 6.5%, and Seagate Technology (NASDAQ:STX) gained 6%, signaling broad strength across the memory and storage complex this morning.
The catalyst is geopolitical. President Trump said Sunday that a peace deal with Iran is complete, with a formal signing referenced for June 19. The agreement is expected to end months of conflict and reopen the Strait of Hormuz, sending oil prices lower and U.S. stock futures higher into the open.
Iran Truce Sparks a Rally in Memory Names The risk-on backdrop is amplifying an already powerful AI memory trade. Micron stock has rallied 244% year to date (YTD), emerging as a dominant driver of interest in the memory complex and a sector bellwether throughout this cycle.
Fundamentals are doing the heavy lifting. Micron’s fiscal Q2 2026 results, reported in March, posted revenue of $23.86 billion, up 196% year over year, with GAAP gross margin expanding to 74%. The company guided fiscal Q3 2026 revenue to $33.5 billion at the midpoint.
Micron Technology CEO Sanjay Mehrotra declared, “In the AI era, memory has become a strategic asset for our customers.” That message is resonating today as traders bid up memory names on easing geopolitical risk and a structurally tight supply backdrop.
AI Buildout Keeps Storage in Demand Western Digital, now a pure-play hard drive maker after spinning off SanDisk in February 2025, recently posted fiscal Q3 revenue of $3.34 billion, with non-GAAP gross margin crossing 50% for the first time. The stock has gained 227% YTD.
SanDisk shares have been the standout of the trio, up 734% YTD. The NAND flash specialist posted fiscal Q3 revenue of $5.95 billion, up 251% year over year, with datacenter revenue of $1.47 billion. CEO David Goeckeler called it “a fundamental inflection point for SanDisk.”
The breakneck pace of AI data center buildout has driven enormous demand for memory components, leading to shortages and pricing power across DRAM, NAND, and HDD. Korean memory giants SK Hynix and Samsung also rose overnight, underscoring the global nature of the move.
What to Watch Next The next anticipated pivot point is Micron’s fiscal Q3 earnings, scheduled for Wednesday, June 24, after market close. Expectations are elevated: Polymarket traders are pricing in a 98% probability of an earnings beat heading into the print.
However, retail sentiment on StockTwits has turned bearish on Micron stock and the DRAM ETF even amid the rally, reflecting concerns about how much upside remains after the sharp run. Polymarket data also shows just a 43% probability of Micron stock closing above $1,000 by month-end, signaling real consolidation risk.
The valuation case is split. Micron’s trailing P/E ratio sits at 46x, but the forward P/E ratio compresses to roughly 10x if guidance plays out, suggesting reasonable value if the AI memory cycle holds. The consensus analyst target of $829 already trails the spot price, which raises the bar for fresh upgrades.
Investors can watch for whether memory and storage names hold their pre-market gains into the close, and whether Micron’s June 24 print validates the AI-driven memory thesis. For traders with existing memory exposure, today’s geopolitical pop may warrant a fresh look at their position sizing given how vertical the sector chart has become.
Halifax, Nova Scotia--(Newsfile Corp. - June 15, 2026) - Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) ("Ucore" or the "Company") is pleased to announce a strategic cooperation framework with Sumitomo Corporation of Americas ("SCOA") to support the development of a diversified rare earth supply chain across North America and allied markets.
Under the Agreement, signed on June 10, 2026, the companies will collaborate on sourcing rare earth feedstock for Ucore's Louisiana Strategic Metals Complex (SMC) and downstream offtake development for separated rare earth products. The focus is on selected middle and heavy rare earth elements critical to high-performance magnets and advanced materials applications primarily in Japan while preserving feedstock for additional processing for North American and allied markets.
The collaboration is intended to combine Ucore's developing RapidSX™ technology platform at its Louisiana ("SMC") rare earth refinery with SCOA's global sourcing, logistics, and market access capabilities, including in Japan, as the parties work to support more diversified rare earth supply chains. Furthermore, the companies intend to formally cooperate as project partners in Ucore's previously announced Global Partnership Initiative with the Government of Canada.
Ucore is advancing its rare earth processing platform in North America, including the development of its planned SMC in Louisiana and continued commercial demonstration with the Government of Canada. SCOA has longstanding experience in the global rare earth industry, including sourcing, trading, and supply chain development.
As part of the framework, SCOA will serve as Ucore's distribution partner for designated separated rare earth products sold to selected customer segments in Japan and other mutually agreed industrial applications.
The companies will work together to explore opportunities for cooperation across the rare earth value chain, subject to mutually agreed commercial terms and existing business arrangements.
# # #
About Ucore Rare Metals Inc.
Ucore is focused on rare- and critical-metal resources, extraction, beneficiation, and separation technologies with the potential for production, growth, and scalability. Ucore's vision and plan is to become a leading advanced technology company, providing best-in-class metal separation products and services to the mining and mineral extraction industry.
Through strategic partnerships, Ucore aims to support the development of a more diversified and resilient North American REE supply chain through the near-term development of a heavy and light rare-earth processing facility in the US State of Louisiana, subsequent SMCs in Canada and Alaska and the longer-term development of Ucore's 100% controlled Bokan-Dotson Ridge Rare Heavy REE Project on Prince of Wales Island in Southeast Alaska, USA ("Bokan").
Ucore is listed on the TSXV under the trading symbol "UCU" and in the United States on the OTC Markets' OTCQX® Best Market under the ticker symbol "UURAF."
For further information, please visit www.ucore.com.
Forward-Looking Statements
This press release contains "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements" within the meaning of applicable Canadian securities laws. All statements in this release (other than statements of historical facts) that address future business development, technological development and/or acquisition activities (including any related required financings), timelines, events, or developments that the Company is pursuing are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance or results, and actual results or developments may differ materially from those in forward-looking statements.
For additional risks and uncertainties regarding the Company, its business activities, its ability to qualify for and receive any additional funding from any U.S. or Canadian government, the CDF and the aforementioned projects (generally), see the risk disclosure in the Company's MD&A for Q1-2026 (filed on SEDAR+ on May 29, 2026) (www.sedarplus.ca) as well as the risks described below.
Regarding the disclosure above in the "About Ucore Rare Metals Inc." section, the Company has assumed that it will be able to procure or retain additional partners and/or suppliers, in addition to Innovation Metals Corp. ("IMC"), as suppliers for Ucore's expected future SMCs. Ucore has also assumed that sufficient external funding will be found to continue and complete the ongoing research and development work required at the CDF and also later prepare a new National Instrument 43-101 technical report that demonstrates that Bokan is feasible and economically viable for the production of both REE and co-product metals and the then prevailing market prices based upon assumed customer offtake agreements. Ucore has also assumed that sufficient external funding will be secured to continue the development of the specific engineering plans for the SMCs and their construction and eventual commissioning and operations.
Forward-looking statements are based on a number of material assumptions, including, without limitation: the successful completion and accuracy of baseline, front-end-engineering design and detailed engineering studies; the ability to complete further engineering, procurement, and construction activities as currently contemplated; the availability, cost, and timely delivery of equipment, materials, utilities, labour and construction services; the Company's ability to secure sufficient financing on acceptable terms; the receipt and timing of all required permits and approvals; the successful scale-up and commercial deployment of RapidSX™ technology from demonstration to commercial operation; the availability of qualified feedstock from third-party suppliers; successful customer qualification and offtake discussions; continued support from governmental partners; and general economic, market, and industry conditions, including assumptions regarding rare earth oxide prices, which are subject to significant volatility.
Although the Company believes that the assumptions underlying the forward-looking information are reasonable, there can be no assurance that such assumptions will prove to be accurate or that the anticipated results, performance, or achievements will be realized. Actual results may differ materially from those expressed or implied by the forward-looking information.
Factors that could cause actual results to differ materially include, without limitation: risks associated with the development, scale-up, and commercialization of new or unproven technologies; the risk that RapidSX™ may not perform at commercial scale as expected; engineering design changes; inaccuracies in capital or operating cost estimates; cost escalation due to inflation, supply chain disruption, or market conditions; delays or failures in procurement, construction, or commissioning; the inability to obtain or maintain required permits, approvals, or regulatory authorizations; challenges in securing adequate financing; adverse capital market conditions; variability in feedstock supply, quality, or pricing; failure to secure or maintain commercial relationships, customer qualification, or offtake arrangements; fluctuations and uncertainty in rare earth oxide prices and demand; the risk that indicative or quoted market prices, including for ex-China markets, may not be realized; operational risks once in production, including equipment failures or lower-than-expected recoveries; geopolitical risk; changes in applicable laws or regulations; environmental or permitting challenges; loss of key personnel; and general economic, business, or competitive conditions.
Neither the TSXV nor its Regulation Services Provider (as that term is defined by the TSXV) accept responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301482
Source: Ucore Rare Metals Inc.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
